Clinical trial results:
A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA Class II-IV) with preserved ejection fraction

Summary

EudraCT number	2013-001747-31
Trial protocol	SK HU AT BG DE ES NO GB NL CZ IT SE BE DK GR FI HR PL SI
Global end of trial date	07 June 2019

Results information

Result version number	v1 (current)
This version publication date	21 June 2020
First version publication date	21 June 2020

Trial information

Trial identification

Sponsor protocol code	CLCZ696D2301

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01920711
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Novartis Pharma AG
Sponsor organisation address	CH-4002, Basel, Switzerland,
Public contact	Clinical Disclosure Office, Novartis Pharma AG, 41 613241111, Novartis.email@novartis.com
Scientific contact	Clinical Disclosure Office, Clinical Disclosure Office, 41 613241111, Novartis.email@novartis.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	07 June 2019
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	07 June 2019
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The primary objective of this study was to compare sacubitril/valsartan to valsartan in reducing the rate of the composite endpoint of cardiovascular (CV) death and total (first and recurrent) heart failure (HF) hospitalizations, in HF patients (NYHA Class II-IV) with preserved ejection fraction (LVEF ≥ 45%).

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines. All the local regulatory requirements pertinent to safety of trial subjects were also followed during the conduct of the trial.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	18 July 2014
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Argentina: 110
Country: Number of subjects enrolled	Australia: 24
Country: Number of subjects enrolled	Austria: 42
Country: Number of subjects enrolled	Belgium: 65
Country: Number of subjects enrolled	Brazil: 109
Country: Number of subjects enrolled	Bulgaria: 363
Country: Number of subjects enrolled	Canada: 79
Country: Number of subjects enrolled	China: 265
Country: Number of subjects enrolled	Colombia: 12
Country: Number of subjects enrolled	Croatia: 60
Country: Number of subjects enrolled	Czech Republic: 241
Country: Number of subjects enrolled	Denmark: 36
Country: Number of subjects enrolled	Finland: 8
Country: Number of subjects enrolled	France: 38
Country: Number of subjects enrolled	Germany: 388
Country: Number of subjects enrolled	Greece: 63
Country: Number of subjects enrolled	Guatemala: 47
Country: Number of subjects enrolled	Hungary: 252

Country: Number of subjects enrolled	India: 79
Country: Number of subjects enrolled	Israel: 83
Country: Number of subjects enrolled	Italy: 204
Country: Number of subjects enrolled	Japan: 79
Country: Number of subjects enrolled	Korea, Republic of: 48
Country: Number of subjects enrolled	Mexico: 60
Country: Number of subjects enrolled	Netherlands: 102
Country: Number of subjects enrolled	Norway: 14
Country: Number of subjects enrolled	Peru: 32
Country: Number of subjects enrolled	Philippines: 33
Country: Number of subjects enrolled	Poland: 180
Country: Number of subjects enrolled	Romania: 110
Country: Number of subjects enrolled	Russian Federation: 170
Country: Number of subjects enrolled	Serbia: 19
Country: Number of subjects enrolled	Singapore: 20
Country: Number of subjects enrolled	Slovakia: 310
Country: Number of subjects enrolled	Slovenia: 13
Country: Number of subjects enrolled	South Africa: 70
Country: Number of subjects enrolled	Spain: 254
Country: Number of subjects enrolled	Sweden: 41
Country: Number of subjects enrolled	Switzerland: 12
Country: Number of subjects enrolled	Taiwan: 61
Country: Number of subjects enrolled	Turkey: 23
Country: Number of subjects enrolled	United Kingdom: 123
Country: Number of subjects enrolled	United States: 480
Worldwide total number of subjects	4822
EEA total number of subjects	2907

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	830
From 65 to 84 years	3992
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

10, 359 patients were screened. 5747 patients were in the Enrolled set. 5746 patients entered valsartan run-in epoch, 5205 patients entered LCZ696 run-in epoch. 4822 patients who completed run-in were randomized at 755 sites in 43 countries. 2419 into the LCZ696 treatment group and 2403 into the valsartan treatment group.

Pre-assignment

Screening details:

10, 359 patients were screened. 5747 patients were in the Enrolled set. 5746 patients entered valsartan run-in epoch, 5205 patients entered LCZ696 run-in epoch. 4822 patients who completed run-in were randomized at 755 sites in 43 countries. 2419 into the LCZ696 treatment group and 2403 into the valsartan treatment group.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor

Arms

Are arms mutually exclusive?	Yes
Arm title	LCZ696

Arm description:

Single Blind Run-in Period (3-8 weeks): Prior optional valsartan run-in 40 mg bid for 1-2 weeks for some patients. followed by Valsartan 80 mg bid for 1-2 weeks followed by LCZ696 100 mg bid for 2-4 weeks prior to randomization into the Double Blind period (up to 57 months). Patients could only be randomized from the run-in period if they met all of the run-in safety criteria. Target dose of LCZ696 during the double blind period was 200 mg bid

Arm type	Experimental
Investigational medicinal product name	Sacubitirl/Valsartan
Investigational medicinal product code	LCZ696
Other name	Entresto
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

50 mg

Investigational medicinal product name	Sacubitirl/Valsartan
Investigational medicinal product code	LCZ696
Other name	Entresto
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

100 mg

Investigational medicinal product name	Sacubitirl/Valsartan
Investigational medicinal product code	LCZ696
Other name	Entresto
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

200 mg

Investigational medicinal product name	Sacubitril/Valsartan
Investigational medicinal product code	LCZ696
Other name	Entresto
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Placebo to match 50 mg, 100mg, 200 mg

Arm title	Valsartan

Arm description:

Single Blind Run-in Period (3-8 weeks): Prior optional valsartan run-in 40 mg bid for 1-2 weeks for some patients, followed by Valsartan 80 mg bid. for 1-2 weeks followed by LCZ696 100 mg bid for 2-4 weeks prior to randomization into the Double Blind period (up to 57 months). Patients could only be randomized from the run-in period if they met all of the run-in safety criteria. Target dose of Valsartan during the double blind period was 160 mg bid

Arm type	Experimental
Investigational medicinal product name	Valsartan
Investigational medicinal product code	
Other name	Diovan
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

40 mg

Investigational medicinal product name	Valsartan
Investigational medicinal product code	
Other name	Diovan
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

80 mg

Investigational medicinal product name	Valsartan
Investigational medicinal product code	
Other name	Diovan
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

160 mg

Investigational medicinal product name	Valsartan
Investigational medicinal product code	
Other name	Diovan
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Placebo to match 40 mg, 80 mg, 160 mg

Number of subjects in period 1	LCZ696	Valsartan
Started	2419	2403
Completed	2055	2030
Not completed	364	373
Adverse event, serious fatal	347	356
Consent withdrawn by subject	4	3
Lost to follow-up	13	14

Baseline characteristics

Reporting groups	
Reporting group title	LCZ696
Reporting group description:	
Single Blind Run-in Period (3-8 weeks): Prior optional valsartan run-in 40 mg bid for 1-2 weeks for some patients. followed by Valsartan 80 mg bid for 1-2 weeks followed by LCZ696 100 mg bid for 2-4 weeks prior to randomization into the Double Blind period (up to 57 months). Patients could only be randomized from the run-in period if they met all of the run-in safety criteria. Target dose of LCZ696 during the double blind period was 200 mg bid	
Reporting group title	Valsartan
Reporting group description:	
Single Blind Run-in Period (3-8 weeks): Prior optional valsartan run-in 40 mg bid for 1-2 weeks for some patients, followed by Valsartan 80 mg bid. for 1-2 weeks followed by LCZ696 100 mg bid for 2-4 weeks prior to randomization into the Double Blind period (up to 57 months). Patients could only be randomized from the run-in period if they met all of the run-in safety criteria. Target dose of Valsartan during the double blind period was 160 mg bid	

Reporting group values	LCZ696	Valsartan	Total
Number of subjects	2419	2403	4822
Age Categorical Units:			
<=18 years	0	0	0
Between 18 and 65 years	415	415	830
>=65 years	2004	1988	3992
Sex: Female, Male Units: Participants			
Female	1247	1244	2491
Male	1172	1159	2331
Race/Ethnicity, Customized Units: Subjects			
Caucasian	1975	1958	3933
Black	52	50	102
Asian	297	310	607
Native American	28	23	51
Pacific Islander	0	1	1
Other	67	61	128

End points

End points reporting groups

Reporting group title	LCZ696

Reporting group description:

Single Blind Run-in Period (3-8 weeks): Prior optional valsartan run-in 40 mg bid for 1-2 weeks for some patients. followed by Valsartan 80 mg bid for 1-2 weeks followed by LCZ696 100 mg bid for 2-4 weeks prior to randomization into the Double Blind period (up to 57 months). Patients could only be randomized from the run-in period if they met all of the run-in safety criteria. Target dose of LCZ696 during the double blind period was 200 mg bid

Reporting group title	Valsartan

Reporting group description:

Single Blind Run-in Period (3-8 weeks): Prior optional valsartan run-in 40 mg bid for 1-2 weeks for some patients, followed by Valsartan 80 mg bid. for 1-2 weeks followed by LCZ696 100 mg bid for 2-4 weeks prior to randomization into the Double Blind period (up to 57 months). Patients could only be randomized from the run-in period if they met all of the run-in safety criteria. Target dose of Valsartan during the double blind period was 160 mg bid

Primary: Cumulative number of primary composite events of cardiovascular (CV) death and total (first and recurrent) HF hospitalizations.

End point title	Cumulative number of primary composite events of cardiovascular (CV) death and total (first and recurrent) HF hospitalizations.

End point description:

The primary objective of this study is to compare LCZ696 to valsartan in reducing the rate of the composite endpoint of CV death and total (first and recurrent) HF hospitalizations, in HF patients (New York Heart Association [NYHA] Class II-IV) with preserved ejection fraction (left ventricular ejection fraction [LVEF] ≥45%). The treatment arm with the lower rate of events will be deemed as having a successful response.

End point type	Primary

End point timeframe:

Total follow up time (up to 57 months)

End point values	LCZ696	Valsartan		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2407	2389		
Units: Number of Events				
Primary Composite Events	894	1009		
Total Hospitalizations for heart failure	690	797		
Cardiovascular death	204	212		

Statistical analyses

Statistical analysis title	Primary Composite Events

Statistical analysis description:

Primary Composite Events

Comparison groups	LCZ696 v Valsartan

Number of subjects included in analysis	4796
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.0587 [1]
Method	Proportional Rates Model (LWYY)
Parameter estimate	Rate Ratio
Point estimate	0.8698
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.7526
upper limit	1.0052

Notes:

[1] - 1-sided p-value 0.0294

Statistical analysis title	Total Hospitalizations for heart failure
Statistical analysis description:	
Total Hospitalizations for heart failure	
Comparison groups	LCZ696 v Valsartan
Number of subjects included in analysis	4796
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.0556 [2]
Method	Joint Frality Model
Parameter estimate	Rate Ratio
Point estimate	0.8511
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.7216
upper limit	1.0039

Notes:

[2] - 1-sided p-value 0.0278

Statistical analysis title	Cardiovascular Death
Statistical analysis description:	
Cardiovascular Death	
Comparison groups	LCZ696 v Valsartan
Number of subjects included in analysis	4796
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.6241 [3]
Method	Cox's proportional hazard model
Parameter estimate	Hazard ratio (HR)
Point estimate	0.9531
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.7863
upper limit	1.1551

Notes:

[3] - 1-sided p-value 0.3120

Secondary: Change in the clinical summary score from baseline to Month 8 by Kansas City Cardiomyopathy Questionnaire (KCCQ)

End point title	Change in the clinical summary score from baseline to Month 8 by Kansas City Cardiomyopathy Questionnaire (KCCQ)

End point description:

The KCCQ is a validated instrument for self-assessment of quality of life and health status in heart failure (HF) patients. The clinical summary score, which is derived from the physical limitations and heart failure (HF) symptoms domains of the KCCQ is a valid measure for assessing the patient's health aspects that may be influenced by CV medications.Evaluation of change from baseline to month 8 in KCCQ a most sensitive, specific, and responsive health-related quality of life measure for heart failure symptoms and physical limitations.

End point type	Secondary

End point timeframe:

Baseline, 8 months

End point values	LCZ696	Valsartan		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2407	2389		
Units: Points on a scale				
least squares mean (standard error)	-1.5073 (± 0.3709)	-2.5338 (± 0.3729)		

Statistical analyses

Statistical analysis title	Clinical Summary Score

Statistical analysis description:

Clinical Summary Score

Comparison groups	LCZ696 v Valsartan
Number of subjects included in analysis	4796
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.051
Method	Mixed models analysis
Parameter estimate	Least Squares Mean of Difference
Point estimate	1.0264
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.0047
upper limit	2.0576

Secondary: Change from baseline to Month 8 in New York Heart Association (NYHA)

functional class

End point title	Change from baseline to Month 8 in New York Heart Association (NYHA) functional class

End point description:

Evaluation of change from baseline to Month 8 in NYHA functional class, a well established grading scale used to classify a heart failure's (HF) patients' level of functionality based on the signs and symptoms of HF exhibited by the patient.

End point type	Secondary

End point timeframe:

Baseline, 8 months

End point values	LCZ696	Valsartan		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2407	2389		
Units: Number of Participants				
Improved (n=2316, 2302)	347	289		
Unchanged (n=2316, 2302)	1767	1792		
Worsened (n=2316, 2302)	202	221		

Statistical analyses

Statistical analysis title	NYHA Class Change

Statistical analysis description:

NYHA Class Change

Comparison groups	LCZ696 v Valsartan
Number of subjects included in analysis	4796
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.0035
Method	Repeated measures cumulative odds model
Parameter estimate	Odds ratio (OR)
Point estimate	1.4475
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.1294
upper limit	1.8552

Secondary: Time to first occurance of a composite renal endpoint

End point title	Time to first occurance of a composite renal endpoint

End point description:

Analyis of composite renal endpoint defined as renal death, or reaching ESRD, or ≥50% decline in eGFR relative to baseline, using Cox's proportional hazards model.

End point type	Secondary

End point timeframe:
Randomization to total follow-up time (up to 57 months)

End point values	LCZ696	Valsartan		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2407	2389		
Units: Participants with first event				
Composite renal endpoint	33	64		
Renal Death	1	1		
Reaching ESRD	7	12		
>=50% decline in eGFR from baseline	27	60		

Statistical analyses

Statistical analysis title	Composite renal endpoint
Statistical analysis description: Composite renal endpoint	
Comparison groups	LCZ696 v Valsartan
Number of subjects included in analysis	4796
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.0014
Method	Cox's proportional hazards model
Parameter estimate	Hazard ratio (HR)
Point estimate	0.5041
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.3312
upper limit	0.7673

Statistical analysis title	Renal Death
Statistical analysis description: Renal Death	
Comparison groups	LCZ696 v Valsartan
Number of subjects included in analysis	4796
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.9588
Method	Cox's proportional hazards model
Parameter estimate	Hazard ratio (HR)
Point estimate	0.9295

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.0581
upper limit	14.861

Statistical analysis title	Reaching ESRD
Statistical analysis description:	
Reaching ESRD	
Comparison groups	LCZ696 v Valsartan
Number of subjects included in analysis	4796
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.2484
Method	Cox's proportional hazards model
Parameter estimate	Hazard ratio (HR)
Point estimate	0.5774
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.2272
upper limit	1.4672

Statistical analysis title	>=50% decline in eGFR from baseline
Statistical analysis description:	
>=50% decline in eGFR from baseline	
Comparison groups	LCZ696 v Valsartan
Number of subjects included in analysis	4796
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.0004
Method	Cox's proportional hazards model
Parameter estimate	Hazard ratio (HR)
Point estimate	0.4407
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.2798
upper limit	0.6942

Secondary: Time to all-cause mortality	
End point title	Time to all-cause mortality
End point description:	
Analysis for all-cause mortality using Cox's proportional hazards model.	

End point type	Secondary
End point timeframe:	
Randomization to total follow up time (up to 57 months)	

End point values	LCZ696	Valsartan		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2407	2389		
Units: Participants with 1st event	342	349		

Statistical analyses

Statistical analysis title	All-cause mortality
Statistical analysis description:	
All-cause mortality	
Comparison groups	LCZ696 v Valsartan
Number of subjects included in analysis	4796
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.6846
Method	Cox's proportional hazards model
Parameter estimate	Hazard ratio (HR)
Point estimate	0.9696
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.8352
upper limit	1.1255

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Adverse events were collected from first dose of study treatment until end of study treatment plus 30 days post treatment, up to maximum duration of approx. 5 years.

Adverse event reporting additional description:

Any sign or symptom that occurs during the study treatment plus the 30 days post treatment. Safety set included all randomized patients minus 1 patient who did not receive study drug: 4821 patients.

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	22.0

Reporting groups

Reporting group title	Valsartan

Reporting group description:

Valsartan

Reporting group title	LCZ696

Reporting group description:

LCZ696

Reporting group title	All patients

Reporting group description:

All patients

Serious adverse events	Valsartan	LCZ696	All patients
Total subjects affected by serious adverse events			
subjects affected / exposed	1416 / 2402 (58.95%)	1424 / 2419 (58.87%)	2840 / 4821 (58.91%)
number of deaths (all causes)	357	347	704
number of deaths resulting from adverse events	5	5	10
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Acute lymphocytic leukaemia			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 2
Acute myeloid leukaemia			
subjects affected / exposed	2 / 2402 (0.08%)	0 / 2419 (0.00%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute promyelocytic leukaemia			

subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Adenocarcinoma			
subjects affected / exposed	3 / 2402 (0.12%)	0 / 2419 (0.00%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 3	0 / 0	0 / 3
Adenocarcinoma gastric			
subjects affected / exposed	1 / 2402 (0.04%)	3 / 2419 (0.12%)	4 / 4821 (0.08%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 2	0 / 2
Adenocarcinoma of colon			
subjects affected / exposed	4 / 2402 (0.17%)	3 / 2419 (0.12%)	7 / 4821 (0.15%)
occurrences causally related to treatment / all	0 / 4	0 / 3	0 / 7
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal cancer stage 0			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
B-cell lymphoma			
subjects affected / exposed	0 / 2402 (0.00%)	2 / 2419 (0.08%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Basal cell carcinoma			
subjects affected / exposed	11 / 2402 (0.46%)	11 / 2419 (0.45%)	22 / 4821 (0.46%)
occurrences causally related to treatment / all	0 / 12	1 / 14	1 / 26
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Benign gastrointestinal neoplasm			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Benign lung neoplasm			

subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Benign pancreatic neoplasm			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Bile duct cancer			
subjects affected / exposed	3 / 2402 (0.12%)	1 / 2419 (0.04%)	4 / 4821 (0.08%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 4
deaths causally related to treatment / all	0 / 3	0 / 0	0 / 3
Bladder cancer			
subjects affected / exposed	5 / 2402 (0.21%)	2 / 2419 (0.08%)	7 / 4821 (0.15%)
occurrences causally related to treatment / all	0 / 6	0 / 2	0 / 8
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 2
Bladder neoplasm			
subjects affected / exposed	2 / 2402 (0.08%)	2 / 2419 (0.08%)	4 / 4821 (0.08%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bladder transitional cell carcinoma			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone cancer			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Bowen's disease			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Brain neoplasm			

subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 2
Brain neoplasm malignant			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Breast angiosarcoma			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Breast cancer			
subjects affected / exposed	8 / 2402 (0.33%)	6 / 2419 (0.25%)	14 / 4821 (0.29%)
occurrences causally related to treatment / all	0 / 9	0 / 6	0 / 15
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 2
Breast neoplasm			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchial carcinoma			
subjects affected / exposed	1 / 2402 (0.04%)	4 / 2419 (0.17%)	5 / 4821 (0.10%)
occurrences causally related to treatment / all	0 / 1	0 / 4	0 / 5
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 2
Carcinoma in situ of skin			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Central nervous system lymphoma			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Cholangiocarcinoma			

subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 2
Chronic lymphocytic leukaemia			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic myeloid leukaemia			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clear cell renal cell carcinoma			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colon adenoma			
subjects affected / exposed	2 / 2402 (0.08%)	0 / 2419 (0.00%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colon cancer			
subjects affected / exposed	4 / 2402 (0.17%)	5 / 2419 (0.21%)	9 / 4821 (0.19%)
occurrences causally related to treatment / all	1 / 4	0 / 5	1 / 9
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 2
Colon cancer metastatic			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Colon neoplasm			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Colorectal cancer			

subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Diffuse large B-cell lymphoma			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Endometrial adenocarcinoma			
subjects affected / exposed	1 / 2402 (0.04%)	2 / 2419 (0.08%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endometrial cancer			
subjects affected / exposed	1 / 2402 (0.04%)	2 / 2419 (0.08%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Fibroma			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gallbladder cancer			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Gallbladder neoplasm			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric cancer			
subjects affected / exposed	4 / 2402 (0.17%)	3 / 2419 (0.12%)	7 / 4821 (0.15%)
occurrences causally related to treatment / all	0 / 4	0 / 3	0 / 7
deaths causally related to treatment / all	0 / 2	0 / 3	0 / 5
Gastric neoplasm			

subjects affected / exposed	2 / 2402 (0.08%)	0 / 2419 (0.00%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal carcinoma			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal neoplasm			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal stromal tumour			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Gastrointestinal tract adenoma			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Glioblastoma			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemangioma of liver			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic cancer			
subjects affected / exposed	1 / 2402 (0.04%)	2 / 2419 (0.08%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 4
deaths causally related to treatment / all	0 / 1	0 / 2	0 / 3
Hepatic cancer metastatic			

subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Hepatic neoplasm			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Hepatocellular carcinoma			
subjects affected / exposed	2 / 2402 (0.08%)	5 / 2419 (0.21%)	7 / 4821 (0.15%)
occurrences causally related to treatment / all	0 / 4	0 / 5	0 / 9
deaths causally related to treatment / all	0 / 1	0 / 2	0 / 3
Hormone-refractory prostate cancer			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal adenocarcinoma			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Invasive breast carcinoma			
subjects affected / exposed	0 / 2402 (0.00%)	2 / 2419 (0.08%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Invasive lobular breast carcinoma			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Invasive papillary breast carcinoma			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Kaposi's sarcoma			

subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngeal cancer			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngeal squamous cell carcinoma			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leiomyoma			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lip and/or oral cavity cancer			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lip squamous cell carcinoma			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lipoma			
subjects affected / exposed	2 / 2402 (0.08%)	3 / 2419 (0.12%)	5 / 4821 (0.10%)
occurrences causally related to treatment / all	0 / 2	0 / 3	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung adenocarcinoma			
subjects affected / exposed	3 / 2402 (0.12%)	1 / 2419 (0.04%)	4 / 4821 (0.08%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung cancer metastatic			

subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Lung carcinoma cell type unspecified stage II			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung neoplasm			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Lung neoplasm malignant			
subjects affected / exposed	10 / 2402 (0.42%)	8 / 2419 (0.33%)	18 / 4821 (0.37%)
occurrences causally related to treatment / all	0 / 10	0 / 8	0 / 18
deaths causally related to treatment / all	0 / 3	0 / 4	0 / 7
Lymphoma			
subjects affected / exposed	2 / 2402 (0.08%)	1 / 2419 (0.04%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphoproliferative disorder			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant mediastinal neoplasm			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Malignant melanoma			
subjects affected / exposed	6 / 2402 (0.25%)	7 / 2419 (0.29%)	13 / 4821 (0.27%)
occurrences causally related to treatment / all	1 / 6	0 / 7	1 / 13
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Malignant neoplasm of unknown primary site			

subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Malignant pleural effusion			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Mantle cell lymphoma			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 5	0 / 0	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mediastinum neoplasm			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Meningioma			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mesothelioma			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Metastases to bone			
subjects affected / exposed	1 / 2402 (0.04%)	2 / 2419 (0.08%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Metastases to central nervous system			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Metastases to liver			

subjects affected / exposed	4 / 2402 (0.17%)	3 / 2419 (0.12%)	7 / 4821 (0.15%)
occurrences causally related to treatment / all	0 / 4	0 / 3	0 / 7
deaths causally related to treatment / all	0 / 2	0 / 1	0 / 3
Metastases to lung			
subjects affected / exposed	1 / 2402 (0.04%)	2 / 2419 (0.08%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 2
Metastases to lymph nodes			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Metastasis			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Metastatic carcinoma of the bladder			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastatic lymphoma			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Metastatic malignant melanoma			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Metastatic squamous cell carcinoma			
subjects affected / exposed	0 / 2402 (0.00%)	2 / 2419 (0.08%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Monoclonal gammopathy			

subjects affected / exposed	2 / 2402 (0.08%)	1 / 2419 (0.04%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 2	1 / 1	1 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myelodysplastic syndrome			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Myeloid leukaemia			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Myeloproliferative neoplasm			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neoplasm malignant			
subjects affected / exposed	2 / 2402 (0.08%)	1 / 2419 (0.04%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 2	0 / 3	0 / 5
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Neoplasm skin			
subjects affected / exposed	2 / 2402 (0.08%)	0 / 2419 (0.00%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 4	0 / 0	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Non-Hodgkin's lymphoma			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Non-small cell lung cancer			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Oesophageal adenocarcinoma			

subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal carcinoma			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oncologic complication			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Oral haemangioma			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oropharyngeal cancer			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Oropharyngeal squamous cell carcinoma			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Ovarian cancer			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Ovarian epithelial cancer			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatic carcinoma			

subjects affected / exposed	2 / 2402 (0.08%)	4 / 2419 (0.17%)	6 / 4821 (0.12%)
occurrences causally related to treatment / all	0 / 2	0 / 4	0 / 6
deaths causally related to treatment / all	0 / 2	0 / 3	0 / 5
Pancreatic neoplasm			
subjects affected / exposed	0 / 2402 (0.00%)	2 / 2419 (0.08%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Papillary thyroid cancer			
subjects affected / exposed	0 / 2402 (0.00%)	2 / 2419 (0.08%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Papilloma			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Parathyroid tumour benign			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Penile cancer			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Plasma cell myeloma			
subjects affected / exposed	3 / 2402 (0.12%)	0 / 2419 (0.00%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	1 / 3	0 / 0	1 / 3
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Prostate cancer			
subjects affected / exposed	8 / 2402 (0.33%)	7 / 2419 (0.29%)	15 / 4821 (0.31%)
occurrences causally related to treatment / all	0 / 8	0 / 7	0 / 15
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prostate cancer metastatic			

subjects affected / exposed	0 / 2402 (0.00%)	2 / 2419 (0.08%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prostatic adenoma			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal adenocarcinoma			
subjects affected / exposed	3 / 2402 (0.12%)	2 / 2419 (0.08%)	5 / 4821 (0.10%)
occurrences causally related to treatment / all	0 / 3	0 / 2	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal cancer			
subjects affected / exposed	4 / 2402 (0.17%)	6 / 2419 (0.25%)	10 / 4821 (0.21%)
occurrences causally related to treatment / all	0 / 4	0 / 6	0 / 10
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 2
Rectal cancer metastatic			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Rectal cancer recurrent			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal neoplasm			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal cancer			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal cell carcinoma			

subjects affected / exposed	1 / 2402 (0.04%)	2 / 2419 (0.08%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal neoplasm			
subjects affected / exposed	0 / 2402 (0.00%)	2 / 2419 (0.08%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sarcoma uterus			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Schwannoma			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seborrhoeic keratosis			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin cancer			
subjects affected / exposed	0 / 2402 (0.00%)	2 / 2419 (0.08%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin neoplasm bleeding			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small cell lung cancer			
subjects affected / exposed	2 / 2402 (0.08%)	2 / 2419 (0.08%)	4 / 4821 (0.08%)
occurrences causally related to treatment / all	0 / 2	0 / 3	0 / 5
deaths causally related to treatment / all	0 / 2	0 / 1	0 / 3
Squamous cell carcinoma			

subjects affected / exposed	8 / 2402 (0.33%)	6 / 2419 (0.25%)	14 / 4821 (0.29%)
occurrences causally related to treatment / all	0 / 10	0 / 7	0 / 17
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma of lung			
subjects affected / exposed	1 / 2402 (0.04%)	4 / 2419 (0.17%)	5 / 4821 (0.10%)
occurrences causally related to treatment / all	0 / 1	1 / 4	1 / 5
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Transitional cell carcinoma			
subjects affected / exposed	4 / 2402 (0.17%)	0 / 2419 (0.00%)	4 / 4821 (0.08%)
occurrences causally related to treatment / all	0 / 4	0 / 0	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transitional cell carcinoma recurrent			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tumour compression			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tumour embolism			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tumour haemorrhage			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Ureteral neoplasm			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ureteric cancer			

subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Uterine cancer			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Uterine leiomyoma			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vaginal adenocarcinoma			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vaginal cancer			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Waldenstrom's macroglobulinaemia			
subjects affected / exposed	2 / 2402 (0.08%)	0 / 2419 (0.00%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Accelerated hypertension			
subjects affected / exposed	2 / 2402 (0.08%)	0 / 2419 (0.00%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angiopathy			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic aneurysm			

subjects affected / exposed	8 / 2402 (0.33%)	2 / 2419 (0.08%)	10 / 4821 (0.21%)
occurrences causally related to treatment / all	0 / 8	0 / 2	0 / 10
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic aneurysm rupture			
subjects affected / exposed	1 / 2402 (0.04%)	2 / 2419 (0.08%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 1	0 / 2	0 / 3
Aortic dissection			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic rupture			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic stenosis			
subjects affected / exposed	12 / 2402 (0.50%)	13 / 2419 (0.54%)	25 / 4821 (0.52%)
occurrences causally related to treatment / all	0 / 12	0 / 13	0 / 25
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Aortic thrombosis			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arterial occlusive disease			
subjects affected / exposed	1 / 2402 (0.04%)	2 / 2419 (0.08%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arteriosclerosis			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bleeding varicose vein			

subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood pressure fluctuation			
subjects affected / exposed	2 / 2402 (0.08%)	0 / 2419 (0.00%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Circulatory collapse			
subjects affected / exposed	2 / 2402 (0.08%)	3 / 2419 (0.12%)	5 / 4821 (0.10%)
occurrences causally related to treatment / all	0 / 2	1 / 3	1 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Deep vein thrombosis			
subjects affected / exposed	7 / 2402 (0.29%)	4 / 2419 (0.17%)	11 / 4821 (0.23%)
occurrences causally related to treatment / all	1 / 8	0 / 4	1 / 12
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dry gangrene			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Essential hypertension			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Extremity necrosis			
subjects affected / exposed	0 / 2402 (0.00%)	2 / 2419 (0.08%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematoma			
subjects affected / exposed	8 / 2402 (0.33%)	7 / 2419 (0.29%)	15 / 4821 (0.31%)
occurrences causally related to treatment / all	0 / 8	0 / 7	0 / 15
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Haemorrhage			

subjects affected / exposed	1 / 2402 (0.04%)	2 / 2419 (0.08%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhagic infarction			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertension			
subjects affected / exposed	25 / 2402 (1.04%)	16 / 2419 (0.66%)	41 / 4821 (0.85%)
occurrences causally related to treatment / all	0 / 30	0 / 16	0 / 46
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertensive crisis			
subjects affected / exposed	8 / 2402 (0.33%)	4 / 2419 (0.17%)	12 / 4821 (0.25%)
occurrences causally related to treatment / all	0 / 9	0 / 6	0 / 15
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertensive emergency			
subjects affected / exposed	3 / 2402 (0.12%)	1 / 2419 (0.04%)	4 / 4821 (0.08%)
occurrences causally related to treatment / all	0 / 4	0 / 1	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Hypertensive urgency			
subjects affected / exposed	1 / 2402 (0.04%)	6 / 2419 (0.25%)	7 / 4821 (0.15%)
occurrences causally related to treatment / all	0 / 1	0 / 6	0 / 7
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	47 / 2402 (1.96%)	52 / 2419 (2.15%)	99 / 4821 (2.05%)
occurrences causally related to treatment / all	22 / 52	24 / 60	46 / 112
deaths causally related to treatment / all	0 / 1	1 / 3	1 / 4
Hypovolaemic shock			
subjects affected / exposed	2 / 2402 (0.08%)	1 / 2419 (0.04%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Iliac artery embolism			

subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intermittent claudication			
subjects affected / exposed	1 / 2402 (0.04%)	2 / 2419 (0.08%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemia			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Jugular vein thrombosis			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leriche syndrome			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphoedema			
subjects affected / exposed	4 / 2402 (0.17%)	0 / 2419 (0.00%)	4 / 4821 (0.08%)
occurrences causally related to treatment / all	0 / 4	0 / 0	0 / 4
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Orthostatic hypertension			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Orthostatic hypotension			
subjects affected / exposed	9 / 2402 (0.37%)	5 / 2419 (0.21%)	14 / 4821 (0.29%)
occurrences causally related to treatment / all	3 / 9	1 / 5	4 / 14
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral arterial occlusive disease			

subjects affected / exposed	7 / 2402 (0.29%)	18 / 2419 (0.74%)	25 / 4821 (0.52%)
occurrences causally related to treatment / all	0 / 9	0 / 19	0 / 28
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral artery aneurysm			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral artery occlusion			
subjects affected / exposed	2 / 2402 (0.08%)	2 / 2419 (0.08%)	4 / 4821 (0.08%)
occurrences causally related to treatment / all	0 / 2	0 / 3	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral artery stenosis			
subjects affected / exposed	4 / 2402 (0.17%)	3 / 2419 (0.12%)	7 / 4821 (0.15%)
occurrences causally related to treatment / all	0 / 5	0 / 4	0 / 9
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral artery thrombosis			
subjects affected / exposed	2 / 2402 (0.08%)	2 / 2419 (0.08%)	4 / 4821 (0.08%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral coldness			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral embolism			
subjects affected / exposed	3 / 2402 (0.12%)	3 / 2419 (0.12%)	6 / 4821 (0.12%)
occurrences causally related to treatment / all	0 / 3	1 / 3	1 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral ischaemia			
subjects affected / exposed	7 / 2402 (0.29%)	8 / 2419 (0.33%)	15 / 4821 (0.31%)
occurrences causally related to treatment / all	0 / 8	0 / 9	0 / 17
deaths causally related to treatment / all	0 / 0	0 / 2	0 / 2
Peripheral vascular disorder			

subjects affected / exposed	2 / 2402 (0.08%)	5 / 2419 (0.21%)	7 / 4821 (0.15%)
occurrences causally related to treatment / all	0 / 2	0 / 7	0 / 9
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral venous disease			
subjects affected / exposed	0 / 2402 (0.00%)	2 / 2419 (0.08%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Phlebitis			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post thrombotic syndrome			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Shock			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Shock haemorrhagic			
subjects affected / exposed	5 / 2402 (0.21%)	2 / 2419 (0.08%)	7 / 4821 (0.15%)
occurrences causally related to treatment / all	0 / 5	0 / 2	0 / 7
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 2
Subclavian artery stenosis			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subclavian artery thrombosis			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Temporal arteritis			

subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombosis			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Varicose ulceration			
subjects affected / exposed	2 / 2402 (0.08%)	0 / 2419 (0.00%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Venous thrombosis			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Adverse drug reaction			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asthenia			
subjects affected / exposed	21 / 2402 (0.87%)	12 / 2419 (0.50%)	33 / 4821 (0.68%)
occurrences causally related to treatment / all	3 / 23	0 / 12	3 / 35
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Cardiac death			
subjects affected / exposed	6 / 2402 (0.25%)	3 / 2419 (0.12%)	9 / 4821 (0.19%)
occurrences causally related to treatment / all	1 / 6	0 / 3	1 / 9
deaths causally related to treatment / all	1 / 6	0 / 3	1 / 9
Catheter site haemorrhage			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest discomfort			

subjects affected / exposed	1 / 2402 (0.04%)	4 / 2419 (0.17%)	5 / 4821 (0.10%)
occurrences causally related to treatment / all	0 / 1	0 / 8	0 / 9
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			
subjects affected / exposed	1 / 2402 (0.04%)	2 / 2419 (0.08%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Concomitant disease progression			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Condition aggravated			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Death			
subjects affected / exposed	23 / 2402 (0.96%)	34 / 2419 (1.41%)	57 / 4821 (1.18%)
occurrences causally related to treatment / all	0 / 23	0 / 34	0 / 57
deaths causally related to treatment / all	0 / 23	0 / 34	0 / 57
Disuse syndrome			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Euthanasia			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 2
Fatigue			
subjects affected / exposed	4 / 2402 (0.17%)	4 / 2419 (0.17%)	8 / 4821 (0.17%)
occurrences causally related to treatment / all	0 / 4	0 / 8	0 / 12
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gait disturbance			

subjects affected / exposed	3 / 2402 (0.12%)	3 / 2419 (0.12%)	6 / 4821 (0.12%)
occurrences causally related to treatment / all	0 / 3	0 / 3	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General physical health deterioration			
subjects affected / exposed	5 / 2402 (0.21%)	9 / 2419 (0.37%)	14 / 4821 (0.29%)
occurrences causally related to treatment / all	0 / 6	1 / 9	1 / 15
deaths causally related to treatment / all	0 / 3	0 / 3	0 / 6
Hyperthermia			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ill-defined disorder			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Impaired healing			
subjects affected / exposed	0 / 2402 (0.00%)	3 / 2419 (0.12%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Impaired self-care			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Implant site haemorrhage			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Incarcerated hernia			
subjects affected / exposed	0 / 2402 (0.00%)	2 / 2419 (0.08%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza like illness			

subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lithiasis			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malaise			
subjects affected / exposed	2 / 2402 (0.08%)	2 / 2419 (0.08%)	4 / 4821 (0.08%)
occurrences causally related to treatment / all	1 / 2	0 / 2	1 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mass			
subjects affected / exposed	3 / 2402 (0.12%)	1 / 2419 (0.04%)	4 / 4821 (0.08%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Medical device discomfort			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple organ dysfunction syndrome			
subjects affected / exposed	7 / 2402 (0.29%)	10 / 2419 (0.41%)	17 / 4821 (0.35%)
occurrences causally related to treatment / all	0 / 7	0 / 10	0 / 17
deaths causally related to treatment / all	0 / 7	0 / 9	0 / 16
Necrosis			
subjects affected / exposed	0 / 2402 (0.00%)	2 / 2419 (0.08%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Non-cardiac chest pain			
subjects affected / exposed	37 / 2402 (1.54%)	42 / 2419 (1.74%)	79 / 4821 (1.64%)
occurrences causally related to treatment / all	0 / 51	0 / 51	0 / 102
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oedema			

subjects affected / exposed	0 / 2402 (0.00%)	2 / 2419 (0.08%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oedema peripheral			
subjects affected / exposed	12 / 2402 (0.50%)	6 / 2419 (0.25%)	18 / 4821 (0.37%)
occurrences causally related to treatment / all	0 / 12	0 / 6	0 / 18
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain			
subjects affected / exposed	3 / 2402 (0.12%)	1 / 2419 (0.04%)	4 / 4821 (0.08%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Peripheral swelling			
subjects affected / exposed	3 / 2402 (0.12%)	1 / 2419 (0.04%)	4 / 4821 (0.08%)
occurrences causally related to treatment / all	0 / 4	0 / 1	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	13 / 2402 (0.54%)	8 / 2419 (0.33%)	21 / 4821 (0.44%)
occurrences causally related to treatment / all	0 / 14	0 / 10	0 / 24
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Stenosis			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sudden cardiac death			
subjects affected / exposed	16 / 2402 (0.67%)	15 / 2419 (0.62%)	31 / 4821 (0.64%)
occurrences causally related to treatment / all	1 / 16	0 / 15	1 / 31
deaths causally related to treatment / all	1 / 16	0 / 15	1 / 31
Sudden death			
subjects affected / exposed	22 / 2402 (0.92%)	21 / 2419 (0.87%)	43 / 4821 (0.89%)
occurrences causally related to treatment / all	1 / 22	0 / 21	1 / 43
deaths causally related to treatment / all	1 / 22	0 / 21	1 / 43
Surgical failure			

subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Swelling			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Systemic inflammatory response syndrome			
subjects affected / exposed	5 / 2402 (0.21%)	1 / 2419 (0.04%)	6 / 4821 (0.12%)
occurrences causally related to treatment / all	0 / 5	0 / 1	0 / 6
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Treatment noncompliance			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ulcer haemorrhage			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Unevaluable event			
subjects affected / exposed	3 / 2402 (0.12%)	0 / 2419 (0.00%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular stent stenosis			
subjects affected / exposed	2 / 2402 (0.08%)	1 / 2419 (0.04%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Anaphylactic reaction			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaphylactic shock			

subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug hypersensitivity			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Food allergy			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	1 / 2	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sarcoidosis			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Social circumstances			
Immobile			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Living in residential institution			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Adenomyosis			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Benign prostatic hyperplasia			
subjects affected / exposed	5 / 2402 (0.21%)	8 / 2419 (0.33%)	13 / 4821 (0.27%)
occurrences causally related to treatment / all	0 / 5	0 / 8	0 / 13
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Breast calcifications			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Breast cyst			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Breast mass			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cervical dysplasia			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cervical polyp			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endometrial hyperplasia			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endometrial thickening			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erectile dysfunction			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metrorrhagia			

subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ovarian cyst			
subjects affected / exposed	1 / 2402 (0.04%)	2 / 2419 (0.08%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postmenopausal haemorrhage			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prostatic haemorrhage			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prostatic obstruction			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prostatitis			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Scrotal inflammation			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spermatocele			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Uterine polyp			

subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Uterine prolapse			
subjects affected / exposed	0 / 2402 (0.00%)	2 / 2419 (0.08%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vaginal haemorrhage			
subjects affected / exposed	0 / 2402 (0.00%)	2 / 2419 (0.08%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vaginal prolapse			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Acute pulmonary oedema			
subjects affected / exposed	14 / 2402 (0.58%)	12 / 2419 (0.50%)	26 / 4821 (0.54%)
occurrences causally related to treatment / all	0 / 15	0 / 13	0 / 28
deaths causally related to treatment / all	0 / 1	0 / 3	0 / 4
Acute respiratory distress syndrome			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute respiratory failure			
subjects affected / exposed	24 / 2402 (1.00%)	20 / 2419 (0.83%)	44 / 4821 (0.91%)
occurrences causally related to treatment / all	0 / 28	0 / 22	0 / 50
deaths causally related to treatment / all	0 / 9	0 / 7	0 / 16
Aspiration			
subjects affected / exposed	2 / 2402 (0.08%)	1 / 2419 (0.04%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 2
Asthma			

subjects affected / exposed	10 / 2402 (0.42%)	9 / 2419 (0.37%)	19 / 4821 (0.39%)
occurrences causally related to treatment / all	0 / 14	0 / 10	0 / 24
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atelectasis			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchial hyperreactivity			
subjects affected / exposed	0 / 2402 (0.00%)	2 / 2419 (0.08%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Bronchial obstruction			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchiectasis			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Bronchitis chronic			
subjects affected / exposed	3 / 2402 (0.12%)	0 / 2419 (0.00%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchospasm			
subjects affected / exposed	2 / 2402 (0.08%)	2 / 2419 (0.08%)	4 / 4821 (0.08%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 4
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Chronic obstructive pulmonary disease			
subjects affected / exposed	67 / 2402 (2.79%)	42 / 2419 (1.74%)	109 / 4821 (2.26%)
occurrences causally related to treatment / all	1 / 92	0 / 65	1 / 157
deaths causally related to treatment / all	0 / 4	0 / 1	0 / 5
Chronic respiratory failure			

subjects affected / exposed	4 / 2402 (0.17%)	3 / 2419 (0.12%)	7 / 4821 (0.15%)
occurrences causally related to treatment / all	0 / 4	0 / 3	0 / 7
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 2
Cough			
subjects affected / exposed	3 / 2402 (0.12%)	3 / 2419 (0.12%)	6 / 4821 (0.12%)
occurrences causally related to treatment / all	0 / 3	0 / 3	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Dyspnoea			
subjects affected / exposed	64 / 2402 (2.66%)	42 / 2419 (1.74%)	106 / 4821 (2.20%)
occurrences causally related to treatment / all	2 / 75	0 / 50	2 / 125
deaths causally related to treatment / all	0 / 6	0 / 1	0 / 7
Dyspnoea at rest			
subjects affected / exposed	3 / 2402 (0.12%)	0 / 2419 (0.00%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea exertional			
subjects affected / exposed	5 / 2402 (0.21%)	4 / 2419 (0.17%)	9 / 4821 (0.19%)
occurrences causally related to treatment / all	0 / 5	0 / 4	0 / 9
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Emphysema			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epistaxis			
subjects affected / exposed	4 / 2402 (0.17%)	4 / 2419 (0.17%)	8 / 4821 (0.17%)
occurrences causally related to treatment / all	0 / 5	0 / 4	0 / 9
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemoptysis			
subjects affected / exposed	5 / 2402 (0.21%)	2 / 2419 (0.08%)	7 / 4821 (0.15%)
occurrences causally related to treatment / all	0 / 5	0 / 2	0 / 7
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Haemothorax			

subjects affected / exposed	2 / 2402 (0.08%)	0 / 2419 (0.00%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hydrothorax			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypercapnia			
subjects affected / exposed	2 / 2402 (0.08%)	2 / 2419 (0.08%)	4 / 4821 (0.08%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 4
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 2
Hypoventilation			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoxia			
subjects affected / exposed	6 / 2402 (0.25%)	2 / 2419 (0.08%)	8 / 4821 (0.17%)
occurrences causally related to treatment / all	0 / 6	0 / 2	0 / 8
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 2
Interstitial lung disease			
subjects affected / exposed	3 / 2402 (0.12%)	4 / 2419 (0.17%)	7 / 4821 (0.15%)
occurrences causally related to treatment / all	0 / 3	0 / 5	0 / 8
deaths causally related to treatment / all	0 / 0	0 / 2	0 / 2
Laryngeal haemorrhage			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngeal oedema			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngospasm			

subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung disorder			
subjects affected / exposed	3 / 2402 (0.12%)	1 / 2419 (0.04%)	4 / 4821 (0.08%)
occurrences causally related to treatment / all	0 / 4	0 / 1	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mediastinal mass			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nasal septum deviation			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obstructive airways disorder			
subjects affected / exposed	2 / 2402 (0.08%)	0 / 2419 (0.00%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Organising pneumonia			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Orthopnoea			
subjects affected / exposed	2 / 2402 (0.08%)	1 / 2419 (0.04%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pharyngeal haemorrhage			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pickwickian syndrome			

subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	15 / 2402 (0.62%)	17 / 2419 (0.70%)	32 / 4821 (0.66%)
occurrences causally related to treatment / all	0 / 17	0 / 23	0 / 40
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Pleurisy			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Pneumonia aspiration			
subjects affected / exposed	11 / 2402 (0.46%)	7 / 2419 (0.29%)	18 / 4821 (0.37%)
occurrences causally related to treatment / all	0 / 11	0 / 8	0 / 19
deaths causally related to treatment / all	0 / 2	0 / 2	0 / 4
Pneumonitis			
subjects affected / exposed	1 / 2402 (0.04%)	2 / 2419 (0.08%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	1 / 2402 (0.04%)	4 / 2419 (0.17%)	5 / 4821 (0.10%)
occurrences causally related to treatment / all	0 / 1	0 / 4	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Presbyphonia			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary alveolar haemorrhage			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary arterial hypertension			

subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary congestion			
subjects affected / exposed	5 / 2402 (0.21%)	0 / 2419 (0.00%)	5 / 4821 (0.10%)
occurrences causally related to treatment / all	0 / 7	0 / 0	0 / 7
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	17 / 2402 (0.71%)	16 / 2419 (0.66%)	33 / 4821 (0.68%)
occurrences causally related to treatment / all	0 / 17	0 / 17	0 / 34
deaths causally related to treatment / all	0 / 4	0 / 4	0 / 8
Pulmonary eosinophilia			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary fibrosis			
subjects affected / exposed	0 / 2402 (0.00%)	3 / 2419 (0.12%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 0	0 / 4	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 2	0 / 2
Pulmonary hypertension			
subjects affected / exposed	9 / 2402 (0.37%)	4 / 2419 (0.17%)	13 / 4821 (0.27%)
occurrences causally related to treatment / all	0 / 10	0 / 5	0 / 15
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Pulmonary mass			
subjects affected / exposed	4 / 2402 (0.17%)	3 / 2419 (0.12%)	7 / 4821 (0.15%)
occurrences causally related to treatment / all	0 / 4	0 / 3	0 / 7
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary oedema			
subjects affected / exposed	16 / 2402 (0.67%)	7 / 2419 (0.29%)	23 / 4821 (0.48%)
occurrences causally related to treatment / all	0 / 17	0 / 7	0 / 24
deaths causally related to treatment / all	0 / 2	0 / 1	0 / 3
Respiratory acidosis			

subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory arrest			
subjects affected / exposed	2 / 2402 (0.08%)	1 / 2419 (0.04%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 2	0 / 1	0 / 3
Respiratory depression			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory distress			
subjects affected / exposed	3 / 2402 (0.12%)	1 / 2419 (0.04%)	4 / 4821 (0.08%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 4
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 2
Respiratory failure			
subjects affected / exposed	32 / 2402 (1.33%)	29 / 2419 (1.20%)	61 / 4821 (1.27%)
occurrences causally related to treatment / all	0 / 39	0 / 32	0 / 71
deaths causally related to treatment / all	0 / 13	0 / 13	0 / 26
Respiratory tract congestion			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sleep apnoea syndrome			
subjects affected / exposed	5 / 2402 (0.21%)	4 / 2419 (0.17%)	9 / 4821 (0.19%)
occurrences causally related to treatment / all	0 / 5	0 / 4	0 / 9
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Status asthmaticus			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tracheal stenosis			

subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vocal cord polyp			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wheezing			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Acute stress disorder			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adjustment disorder			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adjustment disorder with mixed anxiety and depressed mood			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Agitation			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	1 / 1	1 / 1
Alcoholism			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anxiety			

subjects affected / exposed	1 / 2402 (0.04%)	2 / 2419 (0.08%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 1	1 / 2	1 / 3
deaths causally related to treatment / all	0 / 0	1 / 1	1 / 1
Anxiety disorder			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Behaviour disorder			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Completed suicide			
subjects affected / exposed	2 / 2402 (0.08%)	4 / 2419 (0.17%)	6 / 4821 (0.12%)
occurrences causally related to treatment / all	0 / 2	0 / 4	0 / 6
deaths causally related to treatment / all	0 / 2	0 / 4	0 / 6
Confusional state			
subjects affected / exposed	7 / 2402 (0.29%)	6 / 2419 (0.25%)	13 / 4821 (0.27%)
occurrences causally related to treatment / all	1 / 7	2 / 8	3 / 15
deaths causally related to treatment / all	0 / 1	1 / 1	1 / 2
Delirium			
subjects affected / exposed	11 / 2402 (0.46%)	7 / 2419 (0.29%)	18 / 4821 (0.37%)
occurrences causally related to treatment / all	0 / 11	0 / 8	0 / 19
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Delirium febrile			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Delusion			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Depressed mood			

subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Depression			
subjects affected / exposed	7 / 2402 (0.29%)	6 / 2419 (0.25%)	13 / 4821 (0.27%)
occurrences causally related to treatment / all	1 / 11	0 / 7	1 / 18
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Disorientation			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	1 / 1	1 / 2
deaths causally related to treatment / all	0 / 0	1 / 1	1 / 1
Hallucination			
subjects affected / exposed	1 / 2402 (0.04%)	2 / 2419 (0.08%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Major depression			
subjects affected / exposed	2 / 2402 (0.08%)	1 / 2419 (0.04%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mental disorder			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mental disorder due to a general medical condition			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mental status changes			
subjects affected / exposed	5 / 2402 (0.21%)	3 / 2419 (0.12%)	8 / 4821 (0.17%)
occurrences causally related to treatment / all	1 / 8	0 / 3	1 / 11
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Organic brain syndrome			

subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Paranoia			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Personality disorder			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Somatic symptom disorder			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicidal ideation			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicide attempt			
subjects affected / exposed	0 / 2402 (0.00%)	2 / 2419 (0.08%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Product issues			
Device battery issue			
subjects affected / exposed	2 / 2402 (0.08%)	1 / 2419 (0.04%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device breakage			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device damage			

subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device defective			
subjects affected / exposed	2 / 2402 (0.08%)	0 / 2419 (0.00%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device dislocation			
subjects affected / exposed	2 / 2402 (0.08%)	2 / 2419 (0.08%)	4 / 4821 (0.08%)
occurrences causally related to treatment / all	1 / 4	0 / 3	1 / 7
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device failure			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device leakage			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device loosening			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device malfunction			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device occlusion			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lead dislodgement			

subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Bile duct obstruction			
subjects affected / exposed	0 / 2402 (0.00%)	2 / 2419 (0.08%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bile duct stenosis			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bile duct stone			
subjects affected / exposed	4 / 2402 (0.17%)	5 / 2419 (0.21%)	9 / 4821 (0.19%)
occurrences causally related to treatment / all	0 / 4	0 / 6	0 / 10
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Biliary colic			
subjects affected / exposed	1 / 2402 (0.04%)	2 / 2419 (0.08%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Biliary dyskinesia			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholangitis			
subjects affected / exposed	4 / 2402 (0.17%)	4 / 2419 (0.17%)	8 / 4821 (0.17%)
occurrences causally related to treatment / all	0 / 4	0 / 5	0 / 9
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholangitis acute			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 4
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Cholecystitis			

subjects affected / exposed	11 / 2402 (0.46%)	14 / 2419 (0.58%)	25 / 4821 (0.52%)
occurrences causally related to treatment / all	1 / 11	0 / 15	1 / 26
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis acute			
subjects affected / exposed	9 / 2402 (0.37%)	8 / 2419 (0.33%)	17 / 4821 (0.35%)
occurrences causally related to treatment / all	0 / 10	0 / 8	0 / 18
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Cholecystitis chronic			
subjects affected / exposed	2 / 2402 (0.08%)	5 / 2419 (0.21%)	7 / 4821 (0.15%)
occurrences causally related to treatment / all	0 / 2	0 / 5	0 / 7
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholelithiasis			
subjects affected / exposed	19 / 2402 (0.79%)	17 / 2419 (0.70%)	36 / 4821 (0.75%)
occurrences causally related to treatment / all	2 / 19	0 / 19	2 / 38
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Cholelithiasis migration			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholestasis			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	1 / 1	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic hepatic failure			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cirrhosis alcoholic			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 4	0 / 0	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cryptogenic cirrhosis			

subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gallbladder disorder			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Gallbladder rupture			
subjects affected / exposed	0 / 2402 (0.00%)	2 / 2419 (0.08%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemobilia			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic cirrhosis			
subjects affected / exposed	6 / 2402 (0.25%)	4 / 2419 (0.17%)	10 / 4821 (0.21%)
occurrences causally related to treatment / all	0 / 9	0 / 4	0 / 13
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 2
Hepatic cyst			
subjects affected / exposed	6 / 2402 (0.25%)	5 / 2419 (0.21%)	11 / 4821 (0.23%)
occurrences causally related to treatment / all	0 / 6	0 / 5	0 / 11
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic failure			
subjects affected / exposed	4 / 2402 (0.17%)	3 / 2419 (0.12%)	7 / 4821 (0.15%)
occurrences causally related to treatment / all	0 / 4	0 / 3	0 / 7
deaths causally related to treatment / all	0 / 3	0 / 0	0 / 3
Hepatic function abnormal			
subjects affected / exposed	5 / 2402 (0.21%)	5 / 2419 (0.21%)	10 / 4821 (0.21%)
occurrences causally related to treatment / all	0 / 5	0 / 5	0 / 10
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Hepatic lesion			

subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic mass			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic steatosis			
subjects affected / exposed	10 / 2402 (0.42%)	10 / 2419 (0.41%)	20 / 4821 (0.41%)
occurrences causally related to treatment / all	0 / 10	0 / 10	0 / 20
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatitis			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatitis acute			
subjects affected / exposed	2 / 2402 (0.08%)	0 / 2419 (0.00%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disease			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatocellular injury			
subjects affected / exposed	2 / 2402 (0.08%)	1 / 2419 (0.04%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatomegaly			
subjects affected / exposed	2 / 2402 (0.08%)	0 / 2419 (0.00%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Hepatorenal syndrome			

subjects affected / exposed	2 / 2402 (0.08%)	1 / 2419 (0.04%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 2
Hepatosplenomegaly			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Jaundice			
subjects affected / exposed	5 / 2402 (0.21%)	8 / 2419 (0.33%)	13 / 4821 (0.27%)
occurrences causally related to treatment / all	0 / 5	0 / 8	0 / 13
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Jaundice cholestatic			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Liver disorder			
subjects affected / exposed	4 / 2402 (0.17%)	1 / 2419 (0.04%)	5 / 4821 (0.10%)
occurrences causally related to treatment / all	0 / 4	0 / 1	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Liver injury			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nonalcoholic fatty liver disease			
subjects affected / exposed	2 / 2402 (0.08%)	1 / 2419 (0.04%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Portal hypertension			
subjects affected / exposed	2 / 2402 (0.08%)	1 / 2419 (0.04%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	1 / 2	0 / 1	1 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Portal vein thrombosis			

subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Primary biliary cholangitis			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Steatohepatitis			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	2 / 2402 (0.08%)	2 / 2419 (0.08%)	4 / 4821 (0.08%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anticoagulation drug level above therapeutic			
subjects affected / exposed	4 / 2402 (0.17%)	2 / 2419 (0.08%)	6 / 4821 (0.12%)
occurrences causally related to treatment / all	0 / 4	0 / 2	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspartate aminotransferase increased			
subjects affected / exposed	2 / 2402 (0.08%)	4 / 2419 (0.17%)	6 / 4821 (0.12%)
occurrences causally related to treatment / all	1 / 2	0 / 4	1 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bleeding time abnormal			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood bilirubin increased			

subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood creatine phosphokinase increased			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood creatinine increased			
subjects affected / exposed	4 / 2402 (0.17%)	1 / 2419 (0.04%)	5 / 4821 (0.10%)
occurrences causally related to treatment / all	3 / 4	0 / 1	3 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood glucose abnormal			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood glucose decreased			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood glucose fluctuation			
subjects affected / exposed	0 / 2402 (0.00%)	2 / 2419 (0.08%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood glucose increased			
subjects affected / exposed	2 / 2402 (0.08%)	1 / 2419 (0.04%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood osmolarity decreased			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood pressure decreased			

subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood pressure increased			
subjects affected / exposed	1 / 2402 (0.04%)	2 / 2419 (0.08%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood sodium decreased			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood urea increased			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Brain natriuretic peptide increased			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac output decreased			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coagulation time prolonged			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Electrocardiogram QT prolonged			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Electrocardiogram repolarisation abnormality			

subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General physical condition abnormal			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Glomerular filtration rate decreased			
subjects affected / exposed	3 / 2402 (0.12%)	0 / 2419 (0.00%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	2 / 3	0 / 0	2 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemoglobin decreased			
subjects affected / exposed	3 / 2402 (0.12%)	0 / 2419 (0.00%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Heart rate decreased			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Heart rate irregular			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic enzyme increased			
subjects affected / exposed	6 / 2402 (0.25%)	7 / 2419 (0.29%)	13 / 4821 (0.27%)
occurrences causally related to treatment / all	0 / 7	1 / 7	1 / 14
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inflammatory marker increased			
subjects affected / exposed	2 / 2402 (0.08%)	0 / 2419 (0.00%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Influenza virus test positive			

subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
International normalised ratio increased			
subjects affected / exposed	2 / 2402 (0.08%)	3 / 2419 (0.12%)	5 / 4821 (0.10%)
occurrences causally related to treatment / all	0 / 2	0 / 3	0 / 5
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Lipase increased			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial necrosis marker increased			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Platelet count decreased			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Precancerous cells present			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prostatic specific antigen increased			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulse absent			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory rate increased			

subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transaminases increased			
subjects affected / exposed	2 / 2402 (0.08%)	1 / 2419 (0.04%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Troponin I increased			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Troponin T increased			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Troponin increased			
subjects affected / exposed	4 / 2402 (0.17%)	0 / 2419 (0.00%)	4 / 4821 (0.08%)
occurrences causally related to treatment / all	1 / 4	0 / 0	1 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urine output decreased			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventilation/perfusion scan abnormal			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Visual field tests abnormal			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Weight decreased			

subjects affected / exposed	2 / 2402 (0.08%)	0 / 2419 (0.00%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Abdominal injury			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Accident			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Accidental overdose			
subjects affected / exposed	0 / 2402 (0.00%)	2 / 2419 (0.08%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acetabulum fracture			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Alcohol poisoning			
subjects affected / exposed	3 / 2402 (0.12%)	0 / 2419 (0.00%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaemia postoperative			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anastomotic leak			
subjects affected / exposed	2 / 2402 (0.08%)	0 / 2419 (0.00%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anastomotic ulcer			

subjects affected / exposed	0 / 2402 (0.00%)	2 / 2419 (0.08%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Animal bite			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ankle fracture			
subjects affected / exposed	4 / 2402 (0.17%)	7 / 2419 (0.29%)	11 / 4821 (0.23%)
occurrences causally related to treatment / all	0 / 4	0 / 7	0 / 11
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arterial bypass occlusion			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arteriovenous fistula thrombosis			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Avulsion fracture			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone contusion			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Brain herniation			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Carbon monoxide poisoning			

subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac function disturbance postoperative			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Cervical vertebral fracture			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest injury			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clavicle fracture			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Comminuted fracture			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Complications of transplanted kidney			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Concussion			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Contusion			

subjects affected / exposed	3 / 2402 (0.12%)	4 / 2419 (0.17%)	7 / 4821 (0.15%)
occurrences causally related to treatment / all	0 / 4	0 / 4	0 / 8
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary bypass stenosis			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Craniocerebral injury			
subjects affected / exposed	4 / 2402 (0.17%)	3 / 2419 (0.12%)	7 / 4821 (0.15%)
occurrences causally related to treatment / all	0 / 4	0 / 3	0 / 7
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 2
Cystitis radiation			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Extra dose administered			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Extradural haematoma			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye injury			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Facial bones fracture			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fall			

subjects affected / exposed	26 / 2402 (1.08%)	33 / 2419 (1.36%)	59 / 4821 (1.22%)
occurrences causally related to treatment / all	2 / 29	3 / 37	5 / 66
deaths causally related to treatment / all	0 / 1	0 / 2	0 / 3
Femoral neck fracture			
subjects affected / exposed	8 / 2402 (0.33%)	5 / 2419 (0.21%)	13 / 4821 (0.27%)
occurrences causally related to treatment / all	0 / 8	0 / 5	0 / 13
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 2
Femur fracture			
subjects affected / exposed	20 / 2402 (0.83%)	11 / 2419 (0.45%)	31 / 4821 (0.64%)
occurrences causally related to treatment / all	0 / 21	0 / 11	0 / 32
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Foot fracture			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fracture			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fractured coccyx			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal stoma complication			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hand fracture			
subjects affected / exposed	0 / 2402 (0.00%)	2 / 2419 (0.08%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Head injury			

subjects affected / exposed	6 / 2402 (0.25%)	5 / 2419 (0.21%)	11 / 4821 (0.23%)
occurrences causally related to treatment / all	0 / 6	0 / 5	0 / 11
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Hip fracture			
subjects affected / exposed	14 / 2402 (0.58%)	13 / 2419 (0.54%)	27 / 4821 (0.56%)
occurrences causally related to treatment / all	0 / 14	0 / 14	0 / 28
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Humerus fracture			
subjects affected / exposed	7 / 2402 (0.29%)	5 / 2419 (0.21%)	12 / 4821 (0.25%)
occurrences causally related to treatment / all	0 / 7	0 / 5	0 / 12
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypobarism			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Incision site haematoma			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Incisional hernia			
subjects affected / exposed	2 / 2402 (0.08%)	1 / 2419 (0.04%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Joint dislocation			
subjects affected / exposed	3 / 2402 (0.12%)	2 / 2419 (0.08%)	5 / 4821 (0.10%)
occurrences causally related to treatment / all	0 / 4	0 / 2	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ligament injury			

subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ligament sprain			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Limb crushing injury			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Limb injury			
subjects affected / exposed	1 / 2402 (0.04%)	4 / 2419 (0.17%)	5 / 4821 (0.10%)
occurrences causally related to treatment / all	0 / 2	0 / 7	0 / 9
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower limb fracture			
subjects affected / exposed	1 / 2402 (0.04%)	2 / 2419 (0.08%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lumbar vertebral fracture			
subjects affected / exposed	2 / 2402 (0.08%)	3 / 2419 (0.12%)	5 / 4821 (0.10%)
occurrences causally related to treatment / all	0 / 2	0 / 3	0 / 5
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Meniscus injury			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple injuries			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Muscle strain			

subjects affected / exposed	2 / 2402 (0.08%)	0 / 2419 (0.00%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nerve root injury cervical			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Overdose			
subjects affected / exposed	2 / 2402 (0.08%)	4 / 2419 (0.17%)	6 / 4821 (0.12%)
occurrences causally related to treatment / all	0 / 2	0 / 4	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Patella fracture			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pelvic fracture			
subjects affected / exposed	2 / 2402 (0.08%)	1 / 2419 (0.04%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Periprosthetic fracture			
subjects affected / exposed	2 / 2402 (0.08%)	0 / 2419 (0.00%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural complication			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural haematoma			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural haemorrhage			

subjects affected / exposed	1 / 2402 (0.04%)	2 / 2419 (0.08%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural myocardial infarction			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post-traumatic pain			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative hypotension			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative respiratory failure			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Postoperative wound complication			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Procedural pneumothorax			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Procedural vomiting			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pubis fracture			

subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Radiation proctitis			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Radius fracture			
subjects affected / exposed	1 / 2402 (0.04%)	7 / 2419 (0.29%)	8 / 4821 (0.17%)
occurrences causally related to treatment / all	0 / 1	0 / 8	0 / 9
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory fume inhalation disorder			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Rib fracture			
subjects affected / exposed	6 / 2402 (0.25%)	11 / 2419 (0.45%)	17 / 4821 (0.35%)
occurrences causally related to treatment / all	0 / 6	0 / 11	0 / 17
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Road traffic accident			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Scapula fracture			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sedation complication			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Skin abrasion			

subjects affected / exposed	2 / 2402 (0.08%)	0 / 2419 (0.00%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin laceration			
subjects affected / exposed	2 / 2402 (0.08%)	6 / 2419 (0.25%)	8 / 4821 (0.17%)
occurrences causally related to treatment / all	0 / 2	0 / 6	0 / 8
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal compression fracture			
subjects affected / exposed	8 / 2402 (0.33%)	3 / 2419 (0.12%)	11 / 4821 (0.23%)
occurrences causally related to treatment / all	0 / 8	0 / 3	0 / 11
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal fracture			
subjects affected / exposed	2 / 2402 (0.08%)	6 / 2419 (0.25%)	8 / 4821 (0.17%)
occurrences causally related to treatment / all	0 / 2	0 / 6	0 / 8
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Splenic rupture			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stomal hernia			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subdural haematoma			
subjects affected / exposed	8 / 2402 (0.33%)	7 / 2419 (0.29%)	15 / 4821 (0.31%)
occurrences causally related to treatment / all	0 / 8	1 / 10	1 / 18
deaths causally related to treatment / all	0 / 2	0 / 2	0 / 4
Subdural haemorrhage			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tendon rupture			

subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thoracic vertebral fracture			
subjects affected / exposed	1 / 2402 (0.04%)	2 / 2419 (0.08%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tibia fracture			
subjects affected / exposed	2 / 2402 (0.08%)	2 / 2419 (0.08%)	4 / 4821 (0.08%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Toxicity to various agents			
subjects affected / exposed	8 / 2402 (0.33%)	2 / 2419 (0.08%)	10 / 4821 (0.21%)
occurrences causally related to treatment / all	0 / 8	0 / 2	0 / 10
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Traumatic haematoma			
subjects affected / exposed	0 / 2402 (0.00%)	2 / 2419 (0.08%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Traumatic haemothorax			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Traumatic intracranial haemorrhage			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Traumatic liver injury			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ulna fracture			

subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper limb fracture			
subjects affected / exposed	2 / 2402 (0.08%)	2 / 2419 (0.08%)	4 / 4821 (0.08%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 4
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Vascular graft occlusion			
subjects affected / exposed	0 / 2402 (0.00%)	2 / 2419 (0.08%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular pseudoaneurysm			
subjects affected / exposed	3 / 2402 (0.12%)	1 / 2419 (0.04%)	4 / 4821 (0.08%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular pseudoaneurysm ruptured			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound complication			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
Atrial septal defect			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital coronary artery malformation			

subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital megaureter			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal arteriovenous malformation			
subjects affected / exposed	0 / 2402 (0.00%)	2 / 2419 (0.08%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
LUMBAR syndrome			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Phimosis			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vertebral artery hypoplasia			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute coronary syndrome			
subjects affected / exposed	13 / 2402 (0.54%)	11 / 2419 (0.45%)	24 / 4821 (0.50%)
occurrences causally related to treatment / all	0 / 15	1 / 11	1 / 26
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 2
Acute left ventricular failure			
subjects affected / exposed	15 / 2402 (0.62%)	14 / 2419 (0.58%)	29 / 4821 (0.60%)
occurrences causally related to treatment / all	0 / 19	0 / 22	0 / 41
deaths causally related to treatment / all	0 / 3	0 / 0	0 / 3
Acute myocardial infarction			

subjects affected / exposed	54 / 2402 (2.25%)	60 / 2419 (2.48%)	114 / 4821 (2.36%)
occurrences causally related to treatment / all	0 / 61	0 / 69	0 / 130
deaths causally related to treatment / all	0 / 9	0 / 8	0 / 17
Adams-Stokes syndrome			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina pectoris			
subjects affected / exposed	50 / 2402 (2.08%)	42 / 2419 (1.74%)	92 / 4821 (1.91%)
occurrences causally related to treatment / all	1 / 57	1 / 49	2 / 106
deaths causally related to treatment / all	0 / 0	0 / 4	0 / 4
Angina unstable			
subjects affected / exposed	43 / 2402 (1.79%)	50 / 2419 (2.07%)	93 / 4821 (1.93%)
occurrences causally related to treatment / all	0 / 52	0 / 61	0 / 113
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic valve disease			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic valve incompetence			
subjects affected / exposed	2 / 2402 (0.08%)	2 / 2419 (0.08%)	4 / 4821 (0.08%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 4
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Aortic valve stenosis			
subjects affected / exposed	3 / 2402 (0.12%)	4 / 2419 (0.17%)	7 / 4821 (0.15%)
occurrences causally related to treatment / all	0 / 3	0 / 5	0 / 8
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arrhythmia			
subjects affected / exposed	4 / 2402 (0.17%)	4 / 2419 (0.17%)	8 / 4821 (0.17%)
occurrences causally related to treatment / all	0 / 4	1 / 4	1 / 8
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Arrhythmia supraventricular			

subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arteriosclerosis coronary artery			
subjects affected / exposed	4 / 2402 (0.17%)	4 / 2419 (0.17%)	8 / 4821 (0.17%)
occurrences causally related to treatment / all	0 / 6	0 / 6	0 / 12
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	145 / 2402 (6.04%)	162 / 2419 (6.70%)	307 / 4821 (6.37%)
occurrences causally related to treatment / all	4 / 196	8 / 220	12 / 416
deaths causally related to treatment / all	0 / 2	0 / 1	0 / 3
Atrial flutter			
subjects affected / exposed	23 / 2402 (0.96%)	31 / 2419 (1.28%)	54 / 4821 (1.12%)
occurrences causally related to treatment / all	1 / 27	2 / 38	3 / 65
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Atrial tachycardia			
subjects affected / exposed	2 / 2402 (0.08%)	7 / 2419 (0.29%)	9 / 4821 (0.19%)
occurrences causally related to treatment / all	0 / 2	0 / 9	0 / 11
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial thrombosis			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrioventricular block			
subjects affected / exposed	4 / 2402 (0.17%)	6 / 2419 (0.25%)	10 / 4821 (0.21%)
occurrences causally related to treatment / all	0 / 4	0 / 6	0 / 10
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrioventricular block complete			
subjects affected / exposed	11 / 2402 (0.46%)	8 / 2419 (0.33%)	19 / 4821 (0.39%)
occurrences causally related to treatment / all	0 / 11	0 / 8	0 / 19
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrioventricular block first degree			

subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrioventricular block second degree			
subjects affected / exposed	3 / 2402 (0.12%)	4 / 2419 (0.17%)	7 / 4821 (0.15%)
occurrences causally related to treatment / all	0 / 3	0 / 4	0 / 7
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bradyarrhythmia			
subjects affected / exposed	3 / 2402 (0.12%)	3 / 2419 (0.12%)	6 / 4821 (0.12%)
occurrences causally related to treatment / all	0 / 3	0 / 3	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Bradycardia			
subjects affected / exposed	24 / 2402 (1.00%)	27 / 2419 (1.12%)	51 / 4821 (1.06%)
occurrences causally related to treatment / all	1 / 26	0 / 27	1 / 53
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Bundle branch block left			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac amyloidosis			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Cardiac arrest			
subjects affected / exposed	30 / 2402 (1.25%)	17 / 2419 (0.70%)	47 / 4821 (0.97%)
occurrences causally related to treatment / all	0 / 30	1 / 17	1 / 47
deaths causally related to treatment / all	0 / 21	1 / 13	1 / 34
Cardiac asthma			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Cardiac discomfort			

subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure			
subjects affected / exposed	380 / 2402 (15.82%)	340 / 2419 (14.06%)	720 / 4821 (14.93%)
occurrences causally related to treatment / all	15 / 652	5 / 529	20 / 1181
deaths causally related to treatment / all	1 / 49	0 / 41	1 / 90
Cardiac failure acute			
subjects affected / exposed	77 / 2402 (3.21%)	85 / 2419 (3.51%)	162 / 4821 (3.36%)
occurrences causally related to treatment / all	1 / 109	1 / 113	2 / 222
deaths causally related to treatment / all	0 / 7	0 / 10	0 / 17
Cardiac failure chronic			
subjects affected / exposed	30 / 2402 (1.25%)	26 / 2419 (1.07%)	56 / 4821 (1.16%)
occurrences causally related to treatment / all	1 / 47	4 / 38	5 / 85
deaths causally related to treatment / all	0 / 4	1 / 5	1 / 9
Cardiac failure congestive			
subjects affected / exposed	83 / 2402 (3.46%)	86 / 2419 (3.56%)	169 / 4821 (3.51%)
occurrences causally related to treatment / all	0 / 155	5 / 146	5 / 301
deaths causally related to treatment / all	0 / 5	0 / 13	0 / 18
Cardiac fibrillation			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac flutter			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac tamponade			
subjects affected / exposed	2 / 2402 (0.08%)	2 / 2419 (0.08%)	4 / 4821 (0.08%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac valve disease			

subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac ventricular disorder			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardio-respiratory arrest			
subjects affected / exposed	13 / 2402 (0.54%)	15 / 2419 (0.62%)	28 / 4821 (0.58%)
occurrences causally related to treatment / all	0 / 13	0 / 15	0 / 28
deaths causally related to treatment / all	0 / 11	0 / 12	0 / 23
Cardiogenic shock			
subjects affected / exposed	6 / 2402 (0.25%)	12 / 2419 (0.50%)	18 / 4821 (0.37%)
occurrences causally related to treatment / all	0 / 6	1 / 12	1 / 18
deaths causally related to treatment / all	0 / 4	0 / 6	0 / 10
Cardiomegaly			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiomyopathy			
subjects affected / exposed	3 / 2402 (0.12%)	0 / 2419 (0.00%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Cardiopulmonary failure			
subjects affected / exposed	1 / 2402 (0.04%)	4 / 2419 (0.17%)	5 / 4821 (0.10%)
occurrences causally related to treatment / all	0 / 1	0 / 4	0 / 5
deaths causally related to treatment / all	0 / 1	0 / 4	0 / 5
Cardiorenal syndrome			
subjects affected / exposed	0 / 2402 (0.00%)	2 / 2419 (0.08%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiovascular disorder			

subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Cardiovascular insufficiency			
subjects affected / exposed	3 / 2402 (0.12%)	1 / 2419 (0.04%)	4 / 4821 (0.08%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 4
deaths causally related to treatment / all	0 / 3	0 / 0	0 / 3
Chronic left ventricular failure			
subjects affected / exposed	1 / 2402 (0.04%)	3 / 2419 (0.12%)	4 / 4821 (0.08%)
occurrences causally related to treatment / all	0 / 1	0 / 4	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congestive cardiomyopathy			
subjects affected / exposed	1 / 2402 (0.04%)	2 / 2419 (0.08%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cor pulmonale			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery disease			
subjects affected / exposed	27 / 2402 (1.12%)	24 / 2419 (0.99%)	51 / 4821 (1.06%)
occurrences causally related to treatment / all	0 / 30	1 / 25	1 / 55
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 2
Coronary artery occlusion			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery stenosis			
subjects affected / exposed	2 / 2402 (0.08%)	5 / 2419 (0.21%)	7 / 4821 (0.15%)
occurrences causally related to treatment / all	0 / 2	0 / 5	0 / 7
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertensive heart disease			

subjects affected / exposed	3 / 2402 (0.12%)	1 / 2419 (0.04%)	4 / 4821 (0.08%)
occurrences causally related to treatment / all	0 / 3	0 / 2	0 / 5
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Intracardiac mass			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic cardiomyopathy			
subjects affected / exposed	1 / 2402 (0.04%)	4 / 2419 (0.17%)	5 / 4821 (0.10%)
occurrences causally related to treatment / all	0 / 1	0 / 4	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Left ventricular dysfunction			
subjects affected / exposed	3 / 2402 (0.12%)	0 / 2419 (0.00%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Left ventricular failure			
subjects affected / exposed	5 / 2402 (0.21%)	6 / 2419 (0.25%)	11 / 4821 (0.23%)
occurrences causally related to treatment / all	0 / 5	0 / 7	0 / 12
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Microvascular coronary artery disease			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mitral valve calcification			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mitral valve incompetence			
subjects affected / exposed	8 / 2402 (0.33%)	7 / 2419 (0.29%)	15 / 4821 (0.31%)
occurrences causally related to treatment / all	0 / 10	1 / 7	1 / 17
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Mitral valve prolapse			

subjects affected / exposed	0 / 2402 (0.00%)	2 / 2419 (0.08%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			
subjects affected / exposed	35 / 2402 (1.46%)	32 / 2419 (1.32%)	67 / 4821 (1.39%)
occurrences causally related to treatment / all	1 / 38	1 / 36	2 / 74
deaths causally related to treatment / all	1 / 13	0 / 11	1 / 24
Myocardial ischaemia			
subjects affected / exposed	11 / 2402 (0.46%)	7 / 2419 (0.29%)	18 / 4821 (0.37%)
occurrences causally related to treatment / all	0 / 11	0 / 7	0 / 18
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 2
Myocardial rupture			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Myocarditis			
subjects affected / exposed	0 / 2402 (0.00%)	2 / 2419 (0.08%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 2	0 / 2
Nodal rhythm			
subjects affected / exposed	2 / 2402 (0.08%)	0 / 2419 (0.00%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Palpitations			
subjects affected / exposed	4 / 2402 (0.17%)	3 / 2419 (0.12%)	7 / 4821 (0.15%)
occurrences causally related to treatment / all	0 / 5	0 / 6	0 / 11
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericardial effusion			
subjects affected / exposed	4 / 2402 (0.17%)	3 / 2419 (0.12%)	7 / 4821 (0.15%)
occurrences causally related to treatment / all	0 / 4	0 / 3	0 / 7
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericarditis			

subjects affected / exposed	2 / 2402 (0.08%)	1 / 2419 (0.04%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericarditis constrictive			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulseless electrical activity			
subjects affected / exposed	1 / 2402 (0.04%)	3 / 2419 (0.12%)	4 / 4821 (0.08%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 4
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 2
Right ventricular dysfunction			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Right ventricular failure			
subjects affected / exposed	3 / 2402 (0.12%)	0 / 2419 (0.00%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 5	0 / 0	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinoatrial block			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinus arrest			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinus bradycardia			
subjects affected / exposed	8 / 2402 (0.33%)	1 / 2419 (0.04%)	9 / 4821 (0.19%)
occurrences causally related to treatment / all	0 / 8	0 / 1	0 / 9
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinus node dysfunction			

subjects affected / exposed	12 / 2402 (0.50%)	18 / 2419 (0.74%)	30 / 4821 (0.62%)
occurrences causally related to treatment / all	0 / 12	0 / 18	0 / 30
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinus tachycardia			
subjects affected / exposed	2 / 2402 (0.08%)	0 / 2419 (0.00%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stress cardiomyopathy			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Supraventricular extrasystoles			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Supraventricular tachycardia			
subjects affected / exposed	3 / 2402 (0.12%)	6 / 2419 (0.25%)	9 / 4821 (0.19%)
occurrences causally related to treatment / all	0 / 3	0 / 11	0 / 14
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Systolic dysfunction			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tachyarrhythmia			
subjects affected / exposed	0 / 2402 (0.00%)	3 / 2419 (0.12%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tachycardia			
subjects affected / exposed	1 / 2402 (0.04%)	3 / 2419 (0.12%)	4 / 4821 (0.08%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Torsade de pointes			

subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tricuspid valve incompetence			
subjects affected / exposed	3 / 2402 (0.12%)	0 / 2419 (0.00%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Trifascicular block			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular arrhythmia			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular dyssynchrony			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular extrasystoles			
subjects affected / exposed	1 / 2402 (0.04%)	2 / 2419 (0.08%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular fibrillation			
subjects affected / exposed	5 / 2402 (0.21%)	4 / 2419 (0.17%)	9 / 4821 (0.19%)
occurrences causally related to treatment / all	0 / 6	0 / 4	0 / 10
deaths causally related to treatment / all	0 / 2	0 / 1	0 / 3
Ventricular tachycardia			
subjects affected / exposed	4 / 2402 (0.17%)	9 / 2419 (0.37%)	13 / 4821 (0.27%)
occurrences causally related to treatment / all	0 / 5	0 / 9	0 / 14
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Nervous system disorders			
Altered state of consciousness			

subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Amyotrophic lateral sclerosis			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aphasia			
subjects affected / exposed	4 / 2402 (0.17%)	1 / 2419 (0.04%)	5 / 4821 (0.10%)
occurrences causally related to treatment / all	0 / 5	0 / 1	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ataxia			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Brain hypoxia			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Brain injury			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 2
Brain oedema			
subjects affected / exposed	1 / 2402 (0.04%)	2 / 2419 (0.08%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Brain stem stroke			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Carotid artery aneurysm			

subjects affected / exposed	2 / 2402 (0.08%)	0 / 2419 (0.00%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Carotid artery disease			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Carotid artery stenosis			
subjects affected / exposed	7 / 2402 (0.29%)	9 / 2419 (0.37%)	16 / 4821 (0.33%)
occurrences causally related to treatment / all	0 / 8	0 / 10	0 / 18
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Carpal tunnel syndrome			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Central nervous system lesion			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebellar haematoma			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Cerebellar infarction			
subjects affected / exposed	2 / 2402 (0.08%)	0 / 2419 (0.00%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebellar ischaemia			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral arteriosclerosis			

subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral artery embolism			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral cyst			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Cerebral haemorrhage			
subjects affected / exposed	6 / 2402 (0.25%)	5 / 2419 (0.21%)	11 / 4821 (0.23%)
occurrences causally related to treatment / all	0 / 6	0 / 5	0 / 11
deaths causally related to treatment / all	0 / 2	0 / 3	0 / 5
Cerebral infarction			
subjects affected / exposed	18 / 2402 (0.75%)	17 / 2419 (0.70%)	35 / 4821 (0.73%)
occurrences causally related to treatment / all	0 / 20	1 / 20	1 / 40
deaths causally related to treatment / all	0 / 0	0 / 2	0 / 2
Cerebral ischaemia			
subjects affected / exposed	3 / 2402 (0.12%)	3 / 2419 (0.12%)	6 / 4821 (0.12%)
occurrences causally related to treatment / all	0 / 3	2 / 3	2 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral thrombosis			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrospinal fluid leakage			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident			

subjects affected / exposed	42 / 2402 (1.75%)	39 / 2419 (1.61%)	81 / 4821 (1.68%)
occurrences causally related to treatment / all	0 / 48	2 / 46	2 / 94
deaths causally related to treatment / all	0 / 8	1 / 10	1 / 18
Cerebrovascular disorder			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular insufficiency			
subjects affected / exposed	1 / 2402 (0.04%)	2 / 2419 (0.08%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 1	0 / 5	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cervical radiculopathy			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cervicobrachial syndrome			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cognitive disorder			
subjects affected / exposed	2 / 2402 (0.08%)	7 / 2419 (0.29%)	9 / 4821 (0.19%)
occurrences causally related to treatment / all	0 / 2	2 / 7	2 / 9
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Coma			
subjects affected / exposed	4 / 2402 (0.17%)	1 / 2419 (0.04%)	5 / 4821 (0.10%)
occurrences causally related to treatment / all	0 / 4	0 / 1	0 / 5
deaths causally related to treatment / all	0 / 2	0 / 1	0 / 3
Dementia			
subjects affected / exposed	1 / 2402 (0.04%)	2 / 2419 (0.08%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Dementia Alzheimer's type			

subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Dementia with Lewy bodies			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Depressed level of consciousness			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetic ketoacidotic hyperglycaemic coma			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetic neuropathy			
subjects affected / exposed	0 / 2402 (0.00%)	2 / 2419 (0.08%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dizziness			
subjects affected / exposed	11 / 2402 (0.46%)	17 / 2419 (0.70%)	28 / 4821 (0.58%)
occurrences causally related to treatment / all	2 / 11	4 / 19	6 / 30
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysarthria			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Embolic stroke			
subjects affected / exposed	4 / 2402 (0.17%)	5 / 2419 (0.21%)	9 / 4821 (0.19%)
occurrences causally related to treatment / all	0 / 4	0 / 5	0 / 9
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Encephalopathy			

subjects affected / exposed	6 / 2402 (0.25%)	1 / 2419 (0.04%)	7 / 4821 (0.15%)
occurrences causally related to treatment / all	0 / 6	0 / 2	0 / 8
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Epilepsy			
subjects affected / exposed	3 / 2402 (0.12%)	0 / 2419 (0.00%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Facial paralysis			
subjects affected / exposed	0 / 2402 (0.00%)	2 / 2419 (0.08%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Generalised tonic-clonic seizure			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Guillain-Barre syndrome			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhage intracranial			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Haemorrhagic cerebral infarction			
subjects affected / exposed	1 / 2402 (0.04%)	2 / 2419 (0.08%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Haemorrhagic stroke			
subjects affected / exposed	3 / 2402 (0.12%)	3 / 2419 (0.12%)	6 / 4821 (0.12%)
occurrences causally related to treatment / all	0 / 3	0 / 3	0 / 6
deaths causally related to treatment / all	0 / 2	0 / 1	0 / 3
Haemorrhagic transformation stroke			

subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache			
subjects affected / exposed	10 / 2402 (0.42%)	3 / 2419 (0.12%)	13 / 4821 (0.27%)
occurrences causally related to treatment / all	0 / 11	0 / 3	0 / 14
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Hemiparesis			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hemiplegia			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Hepatic encephalopathy			
subjects affected / exposed	5 / 2402 (0.21%)	1 / 2419 (0.04%)	6 / 4821 (0.12%)
occurrences causally related to treatment / all	1 / 8	0 / 1	1 / 9
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 2
Hydrocephalus			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoaesthesia			
subjects affected / exposed	0 / 2402 (0.00%)	3 / 2419 (0.12%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoglycaemic coma			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoxic-ischaemic encephalopathy			

subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
IIIrd nerve paralysis			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intracranial aneurysm			
subjects affected / exposed	1 / 2402 (0.04%)	2 / 2419 (0.08%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intracranial haematoma			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intracranial pressure increased			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic cerebral infarction			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Ischaemic stroke			
subjects affected / exposed	29 / 2402 (1.21%)	32 / 2419 (1.32%)	61 / 4821 (1.27%)
occurrences causally related to treatment / all	0 / 29	0 / 36	0 / 65
deaths causally related to treatment / all	0 / 5	0 / 4	0 / 9
Lacunar infarction			
subjects affected / exposed	2 / 2402 (0.08%)	4 / 2419 (0.17%)	6 / 4821 (0.12%)
occurrences causally related to treatment / all	0 / 2	0 / 4	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lacunar stroke			

subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lethargy			
subjects affected / exposed	1 / 2402 (0.04%)	2 / 2419 (0.08%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Loss of consciousness			
subjects affected / exposed	3 / 2402 (0.12%)	3 / 2419 (0.12%)	6 / 4821 (0.12%)
occurrences causally related to treatment / all	0 / 3	1 / 3	1 / 6
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Lumbar radiculopathy			
subjects affected / exposed	2 / 2402 (0.08%)	1 / 2419 (0.04%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lumbosacral radiculopathy			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolic encephalopathy			
subjects affected / exposed	3 / 2402 (0.12%)	6 / 2419 (0.25%)	9 / 4821 (0.19%)
occurrences causally related to treatment / all	0 / 3	0 / 6	0 / 9
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Migraine			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mixed dementia			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Motor dysfunction			

subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Movement disorder			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple system atrophy			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myasthenia gravis			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myasthenic syndrome			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myelopathy			
subjects affected / exposed	0 / 2402 (0.00%)	2 / 2419 (0.08%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myoclonus			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorder			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Neuralgia			

subjects affected / exposed	0 / 2402 (0.00%)	2 / 2419 (0.08%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neuropathy peripheral			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Normal pressure hydrocephalus			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Parkinson's disease			
subjects affected / exposed	1 / 2402 (0.04%)	2 / 2419 (0.08%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Parkinsonism			
subjects affected / exposed	2 / 2402 (0.08%)	0 / 2419 (0.00%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral sensorimotor neuropathy			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Polyneuropathy			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post herpetic neuralgia			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post stroke epilepsy			

subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Posterior reversible encephalopathy syndrome			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Presyncope			
subjects affected / exposed	3 / 2402 (0.12%)	3 / 2419 (0.12%)	6 / 4821 (0.12%)
occurrences causally related to treatment / all	0 / 3	0 / 3	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pseudoradicular syndrome			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Radiculopathy			
subjects affected / exposed	2 / 2402 (0.08%)	2 / 2419 (0.08%)	4 / 4821 (0.08%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Resting tremor			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sciatica			
subjects affected / exposed	4 / 2402 (0.17%)	4 / 2419 (0.17%)	8 / 4821 (0.17%)
occurrences causally related to treatment / all	0 / 4	0 / 5	0 / 9
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	2 / 2402 (0.08%)	6 / 2419 (0.25%)	8 / 4821 (0.17%)
occurrences causally related to treatment / all	0 / 2	0 / 6	0 / 8
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sensory disturbance			

subjects affected / exposed	0 / 2402 (0.00%)	2 / 2419 (0.08%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Somnolence			
subjects affected / exposed	2 / 2402 (0.08%)	0 / 2419 (0.00%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Speech disorder			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal cord compression			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal cord disorder			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spondylitic myelopathy			
subjects affected / exposed	0 / 2402 (0.00%)	2 / 2419 (0.08%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Status epilepticus			
subjects affected / exposed	2 / 2402 (0.08%)	0 / 2419 (0.00%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stroke in evolution			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subarachnoid haemorrhage			

subjects affected / exposed	4 / 2402 (0.17%)	3 / 2419 (0.12%)	7 / 4821 (0.15%)
occurrences causally related to treatment / all	0 / 4	0 / 3	0 / 7
deaths causally related to treatment / all	0 / 2	0 / 1	0 / 3
Syncope			
subjects affected / exposed	57 / 2402 (2.37%)	41 / 2419 (1.69%)	98 / 4821 (2.03%)
occurrences causally related to treatment / all	9 / 67	12 / 44	21 / 111
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Thalamus haemorrhage			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombotic cerebral infarction			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombotic stroke			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Toxic encephalopathy			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transient ischaemic attack			
subjects affected / exposed	26 / 2402 (1.08%)	34 / 2419 (1.41%)	60 / 4821 (1.24%)
occurrences causally related to treatment / all	1 / 26	2 / 37	3 / 63
deaths causally related to treatment / all	0 / 0	1 / 2	1 / 2
Tremor			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Trigeminal neuralgia			

subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Unresponsive to stimuli			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Uraemic encephalopathy			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
VIth nerve paresis			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular dementia			
subjects affected / exposed	2 / 2402 (0.08%)	2 / 2419 (0.08%)	4 / 4821 (0.08%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular parkinsonism			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vertebrobasilar insufficiency			
subjects affected / exposed	2 / 2402 (0.08%)	4 / 2419 (0.17%)	6 / 4821 (0.12%)
occurrences causally related to treatment / all	0 / 2	0 / 4	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vertigo CNS origin			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Acquired haemophilia			

subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaemia			
subjects affected / exposed	67 / 2402 (2.79%)	68 / 2419 (2.81%)	135 / 4821 (2.80%)
occurrences causally related to treatment / all	1 / 77	1 / 83	2 / 160
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 2
Anaemia macrocytic			
subjects affected / exposed	1 / 2402 (0.04%)	2 / 2419 (0.08%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaemia megaloblastic			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaemia vitamin B12 deficiency			
subjects affected / exposed	0 / 2402 (0.00%)	2 / 2419 (0.08%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Autoimmune haemolytic anaemia			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood loss anaemia			
subjects affected / exposed	7 / 2402 (0.29%)	2 / 2419 (0.08%)	9 / 4821 (0.19%)
occurrences causally related to treatment / all	0 / 8	0 / 2	0 / 10
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Coagulopathy			
subjects affected / exposed	2 / 2402 (0.08%)	1 / 2419 (0.04%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Disseminated intravascular coagulation			

subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Hypercoagulation			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypersplenism			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune thrombocytopenic purpura			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Iron deficiency anaemia			
subjects affected / exposed	6 / 2402 (0.25%)	5 / 2419 (0.21%)	11 / 4821 (0.23%)
occurrences causally related to treatment / all	0 / 6	0 / 5	0 / 11
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukocytosis			
subjects affected / exposed	6 / 2402 (0.25%)	1 / 2419 (0.04%)	7 / 4821 (0.15%)
occurrences causally related to treatment / all	0 / 6	0 / 1	0 / 7
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Leukopenia			
subjects affected / exposed	0 / 2402 (0.00%)	2 / 2419 (0.08%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphadenitis			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphadenopathy			

subjects affected / exposed	2 / 2402 (0.08%)	0 / 2419 (0.00%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphadenopathy mediastinal			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Microcytic anaemia			
subjects affected / exposed	1 / 2402 (0.04%)	3 / 2419 (0.12%)	4 / 4821 (0.08%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephrogenic anaemia			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenia			
subjects affected / exposed	1 / 2402 (0.04%)	2 / 2419 (0.08%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Normochromic normocytic anaemia			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancytopenia			
subjects affected / exposed	3 / 2402 (0.12%)	1 / 2419 (0.04%)	4 / 4821 (0.08%)
occurrences causally related to treatment / all	0 / 4	0 / 1	0 / 5
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Splenic infarction			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Splenitis			

subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			
subjects affected / exposed	1 / 2402 (0.04%)	6 / 2419 (0.25%)	7 / 4821 (0.15%)
occurrences causally related to treatment / all	0 / 1	0 / 6	0 / 7
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Thrombocytosis			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			
Deafness unilateral			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sudden hearing loss			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tinnitus			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vertigo			
subjects affected / exposed	3 / 2402 (0.12%)	6 / 2419 (0.25%)	9 / 4821 (0.19%)
occurrences causally related to treatment / all	0 / 3	0 / 6	0 / 9
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vertigo positional			
subjects affected / exposed	1 / 2402 (0.04%)	5 / 2419 (0.21%)	6 / 4821 (0.12%)
occurrences causally related to treatment / all	0 / 1	0 / 6	0 / 7
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vestibular ischaemia			

subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Amaurosis fugax			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blindness unilateral			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cataract			
subjects affected / exposed	12 / 2402 (0.50%)	14 / 2419 (0.58%)	26 / 4821 (0.54%)
occurrences causally related to treatment / all	0 / 14	0 / 14	0 / 28
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cataract diabetic			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Conjunctival haemorrhage			
subjects affected / exposed	3 / 2402 (0.12%)	1 / 2419 (0.04%)	4 / 4821 (0.08%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Entropion			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye pain			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Glaucoma			

subjects affected / exposed	1 / 2402 (0.04%)	2 / 2419 (0.08%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 1	0 / 7	0 / 8
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Macular degeneration			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Macular fibrosis			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Maculopathy			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Narrow anterior chamber angle			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neovascular age-related macular degeneration			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pterygium			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retinal detachment			
subjects affected / exposed	3 / 2402 (0.12%)	1 / 2419 (0.04%)	4 / 4821 (0.08%)
occurrences causally related to treatment / all	0 / 6	0 / 1	0 / 7
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retinal haemorrhage			

subjects affected / exposed	2 / 2402 (0.08%)	1 / 2419 (0.04%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retinal vein occlusion			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vision blurred			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Visual acuity reduced			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vitreous haemorrhage			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal distension			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal hernia			
subjects affected / exposed	1 / 2402 (0.04%)	3 / 2419 (0.12%)	4 / 4821 (0.08%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain			
subjects affected / exposed	8 / 2402 (0.33%)	6 / 2419 (0.25%)	14 / 4821 (0.29%)
occurrences causally related to treatment / all	0 / 8	0 / 6	0 / 14
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain lower			

subjects affected / exposed	2 / 2402 (0.08%)	1 / 2419 (0.04%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain upper			
subjects affected / exposed	4 / 2402 (0.17%)	3 / 2419 (0.12%)	7 / 4821 (0.15%)
occurrences causally related to treatment / all	0 / 4	0 / 4	0 / 8
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Abdominal wall haematoma			
subjects affected / exposed	2 / 2402 (0.08%)	2 / 2419 (0.08%)	4 / 4821 (0.08%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal fissure			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal fistula			
subjects affected / exposed	3 / 2402 (0.12%)	1 / 2419 (0.04%)	4 / 4821 (0.08%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal haemorrhage			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal incontinence			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendiceal mucocoele			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ascites			

subjects affected / exposed	9 / 2402 (0.37%)	8 / 2419 (0.33%)	17 / 4821 (0.35%)
occurrences causally related to treatment / all	1 / 12	0 / 13	1 / 25
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Chronic gastritis			
subjects affected / exposed	3 / 2402 (0.12%)	2 / 2419 (0.08%)	5 / 4821 (0.10%)
occurrences causally related to treatment / all	0 / 3	0 / 2	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	3 / 2402 (0.12%)	5 / 2419 (0.21%)	8 / 4821 (0.17%)
occurrences causally related to treatment / all	0 / 3	0 / 5	0 / 8
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis ischaemic			
subjects affected / exposed	2 / 2402 (0.08%)	1 / 2419 (0.04%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 2
Colitis microscopic			
subjects affected / exposed	0 / 2402 (0.00%)	2 / 2419 (0.08%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis ulcerative			
subjects affected / exposed	0 / 2402 (0.00%)	3 / 2419 (0.12%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	6 / 2402 (0.25%)	2 / 2419 (0.08%)	8 / 4821 (0.17%)
occurrences causally related to treatment / all	0 / 6	0 / 2	0 / 8
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Crohn's disease			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dental caries			

subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetic gastroenteropathy			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diaphragmatic hernia			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	14 / 2402 (0.58%)	13 / 2419 (0.54%)	27 / 4821 (0.56%)
occurrences causally related to treatment / all	0 / 15	0 / 13	0 / 28
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dieulafoy's vascular malformation			
subjects affected / exposed	3 / 2402 (0.12%)	0 / 2419 (0.00%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Diverticular perforation			
subjects affected / exposed	2 / 2402 (0.08%)	1 / 2419 (0.04%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Diverticulum			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulum intestinal			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulum intestinal haemorrhagic			

subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenal polyp			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenal ulcer			
subjects affected / exposed	4 / 2402 (0.17%)	3 / 2419 (0.12%)	7 / 4821 (0.15%)
occurrences causally related to treatment / all	0 / 4	0 / 3	0 / 7
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenal ulcer haemorrhage			
subjects affected / exposed	3 / 2402 (0.12%)	1 / 2419 (0.04%)	4 / 4821 (0.08%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenitis			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspepsia			
subjects affected / exposed	2 / 2402 (0.08%)	3 / 2419 (0.12%)	5 / 4821 (0.10%)
occurrences causally related to treatment / all	0 / 2	0 / 3	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysphagia			
subjects affected / exposed	3 / 2402 (0.12%)	2 / 2419 (0.08%)	5 / 4821 (0.10%)
occurrences causally related to treatment / all	0 / 3	0 / 2	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enteritis			
subjects affected / exposed	1 / 2402 (0.04%)	3 / 2419 (0.12%)	4 / 4821 (0.08%)
occurrences causally related to treatment / all	0 / 2	0 / 3	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erosive oesophagitis			

subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Faecaloma			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Faeces discoloured			
subjects affected / exposed	2 / 2402 (0.08%)	0 / 2419 (0.00%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femoral hernia			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric disorder			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric haemorrhage			
subjects affected / exposed	3 / 2402 (0.12%)	1 / 2419 (0.04%)	4 / 4821 (0.08%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric polyps			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric ulcer			
subjects affected / exposed	3 / 2402 (0.12%)	8 / 2419 (0.33%)	11 / 4821 (0.23%)
occurrences causally related to treatment / all	0 / 3	0 / 8	0 / 11
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric ulcer haemorrhage			

subjects affected / exposed	4 / 2402 (0.17%)	2 / 2419 (0.08%)	6 / 4821 (0.12%)
occurrences causally related to treatment / all	0 / 5	0 / 2	0 / 7
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis			
subjects affected / exposed	7 / 2402 (0.29%)	3 / 2419 (0.12%)	10 / 4821 (0.21%)
occurrences causally related to treatment / all	0 / 8	0 / 4	0 / 12
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis erosive			
subjects affected / exposed	7 / 2402 (0.29%)	1 / 2419 (0.04%)	8 / 4821 (0.17%)
occurrences causally related to treatment / all	0 / 7	0 / 1	0 / 8
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis haemorrhagic			
subjects affected / exposed	2 / 2402 (0.08%)	0 / 2419 (0.00%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	32 / 2402 (1.33%)	29 / 2419 (1.20%)	61 / 4821 (1.27%)
occurrences causally related to treatment / all	1 / 36	0 / 31	1 / 67
deaths causally related to treatment / all	0 / 1	0 / 3	0 / 4
Gastrointestinal perforation			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Gastrointestinal polyp haemorrhage			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal ulcer			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal ulcer haemorrhage			

subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal wall thickening			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrooesophageal reflux disease			
subjects affected / exposed	3 / 2402 (0.12%)	4 / 2419 (0.17%)	7 / 4821 (0.15%)
occurrences causally related to treatment / all	0 / 4	0 / 4	0 / 8
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematemesis			
subjects affected / exposed	1 / 2402 (0.04%)	2 / 2419 (0.08%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Haematochezia			
subjects affected / exposed	3 / 2402 (0.12%)	4 / 2419 (0.17%)	7 / 4821 (0.15%)
occurrences causally related to treatment / all	0 / 3	0 / 5	0 / 8
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhagic erosive gastritis			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhoidal haemorrhage			
subjects affected / exposed	2 / 2402 (0.08%)	0 / 2419 (0.00%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhoids			
subjects affected / exposed	3 / 2402 (0.12%)	5 / 2419 (0.21%)	8 / 4821 (0.17%)
occurrences causally related to treatment / all	0 / 3	0 / 5	0 / 8
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hiatus hernia			

subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileus			
subjects affected / exposed	3 / 2402 (0.12%)	2 / 2419 (0.08%)	5 / 4821 (0.10%)
occurrences causally related to treatment / all	0 / 3	0 / 2	0 / 5
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 2
Ileus paralytic			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Impaired gastric emptying			
subjects affected / exposed	2 / 2402 (0.08%)	0 / 2419 (0.00%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Incarcerated inguinal hernia			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Incarcerated umbilical hernia			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia			
subjects affected / exposed	13 / 2402 (0.54%)	10 / 2419 (0.41%)	23 / 4821 (0.48%)
occurrences causally related to treatment / all	0 / 14	0 / 10	0 / 24
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia, obstructive			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal haemorrhage			

subjects affected / exposed	3 / 2402 (0.12%)	1 / 2419 (0.04%)	4 / 4821 (0.08%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal infarction			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Intestinal ischaemia			
subjects affected / exposed	3 / 2402 (0.12%)	3 / 2419 (0.12%)	6 / 4821 (0.12%)
occurrences causally related to treatment / all	0 / 3	0 / 3	0 / 6
deaths causally related to treatment / all	0 / 2	0 / 1	0 / 3
Intestinal obstruction			
subjects affected / exposed	5 / 2402 (0.21%)	5 / 2419 (0.21%)	10 / 4821 (0.21%)
occurrences causally related to treatment / all	0 / 5	0 / 5	0 / 10
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Intestinal perforation			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Intestinal polyp			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal strangulation			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intra-abdominal haematoma			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intra-abdominal haemorrhage			

subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Irritable bowel syndrome			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestinal obstruction			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestine perforation			
subjects affected / exposed	2 / 2402 (0.08%)	1 / 2419 (0.04%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Large intestine polyp			
subjects affected / exposed	4 / 2402 (0.17%)	5 / 2419 (0.21%)	9 / 4821 (0.19%)
occurrences causally related to treatment / all	0 / 4	0 / 5	0 / 9
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower gastrointestinal haemorrhage			
subjects affected / exposed	6 / 2402 (0.25%)	1 / 2419 (0.04%)	7 / 4821 (0.15%)
occurrences causally related to treatment / all	0 / 6	0 / 1	0 / 7
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mallory-Weiss syndrome			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Melaena			
subjects affected / exposed	6 / 2402 (0.25%)	7 / 2419 (0.29%)	13 / 4821 (0.27%)
occurrences causally related to treatment / all	0 / 8	0 / 8	0 / 16
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Mouth haemorrhage			

subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	5 / 2402 (0.21%)	12 / 2419 (0.50%)	17 / 4821 (0.35%)
occurrences causally related to treatment / all	0 / 6	0 / 15	0 / 21
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obstructive pancreatitis			
subjects affected / exposed	1 / 2402 (0.04%)	2 / 2419 (0.08%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal haemorrhage			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal perforation			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Oesophageal ulcer			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			
subjects affected / exposed	3 / 2402 (0.12%)	2 / 2419 (0.08%)	5 / 4821 (0.10%)
occurrences causally related to treatment / all	0 / 3	0 / 2	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis acute			
subjects affected / exposed	9 / 2402 (0.37%)	5 / 2419 (0.21%)	14 / 4821 (0.29%)
occurrences causally related to treatment / all	1 / 10	0 / 6	1 / 16
deaths causally related to treatment / all	1 / 1	0 / 0	1 / 1
Pancreatitis chronic			

subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis necrotising			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis relapsing			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peptic ulcer haemorrhage			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritoneal haemorrhage			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Portal hypertensive gastropathy			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Proctitis			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal haemorrhage			
subjects affected / exposed	4 / 2402 (0.17%)	9 / 2419 (0.37%)	13 / 4821 (0.27%)
occurrences causally related to treatment / all	0 / 4	0 / 11	0 / 15
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal polyp			

subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal prolapse			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retroperitoneal haematoma			
subjects affected / exposed	1 / 2402 (0.04%)	2 / 2419 (0.08%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Salivary gland calculus			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal haemorrhage			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			
subjects affected / exposed	5 / 2402 (0.21%)	7 / 2419 (0.29%)	12 / 4821 (0.25%)
occurrences causally related to treatment / all	0 / 8	0 / 7	0 / 15
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subileus			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Toothache			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Umbilical hernia			

subjects affected / exposed	2 / 2402 (0.08%)	2 / 2419 (0.08%)	4 / 4821 (0.08%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper gastrointestinal haemorrhage			
subjects affected / exposed	11 / 2402 (0.46%)	7 / 2419 (0.29%)	18 / 4821 (0.37%)
occurrences causally related to treatment / all	0 / 11	0 / 8	0 / 19
deaths causally related to treatment / all	0 / 0	0 / 2	0 / 2
Varices oesophageal			
subjects affected / exposed	2 / 2402 (0.08%)	3 / 2419 (0.12%)	5 / 4821 (0.10%)
occurrences causally related to treatment / all	0 / 2	0 / 3	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	11 / 2402 (0.46%)	9 / 2419 (0.37%)	20 / 4821 (0.41%)
occurrences causally related to treatment / all	1 / 12	0 / 9	1 / 21
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Angioedema			
subjects affected / exposed	1 / 2402 (0.04%)	5 / 2419 (0.21%)	6 / 4821 (0.12%)
occurrences causally related to treatment / all	0 / 1	4 / 5	4 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blister			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Butterfly rash			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Decubitus ulcer			
subjects affected / exposed	1 / 2402 (0.04%)	3 / 2419 (0.12%)	4 / 4821 (0.08%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 4
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Dermatitis			

subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dermatitis exfoliative generalised			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetic foot			
subjects affected / exposed	5 / 2402 (0.21%)	2 / 2419 (0.08%)	7 / 4821 (0.15%)
occurrences causally related to treatment / all	0 / 6	0 / 2	0 / 8
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetic wound			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eczema			
subjects affected / exposed	0 / 2402 (0.00%)	2 / 2419 (0.08%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eczema asteatotic			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erythema			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhage subcutaneous			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperhidrosis			

subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intertrigo			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic skin ulcer			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neurodermatitis			
subjects affected / exposed	1 / 2402 (0.04%)	2 / 2419 (0.08%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Purpura			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rash			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rash maculo-papular			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rash pruritic			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rhinophyma			

subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin lesion			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin ulcer			
subjects affected / exposed	3 / 2402 (0.12%)	5 / 2419 (0.21%)	8 / 4821 (0.17%)
occurrences causally related to treatment / all	0 / 3	0 / 5	0 / 8
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subcutaneous emphysema			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Urticaria			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vasculitic ulcer			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	110 / 2402 (4.58%)	90 / 2419 (3.72%)	200 / 4821 (4.15%)
occurrences causally related to treatment / all	47 / 142	29 / 110	76 / 252
deaths causally related to treatment / all	2 / 12	2 / 9	4 / 21
Anuria			
subjects affected / exposed	0 / 2402 (0.00%)	2 / 2419 (0.08%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Azotaemia			

subjects affected / exposed	3 / 2402 (0.12%)	3 / 2419 (0.12%)	6 / 4821 (0.12%)
occurrences causally related to treatment / all	0 / 3	0 / 3	0 / 6
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Bladder diverticulum			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bladder neck obstruction			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bladder prolapse			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Calculus bladder			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Calculus urethral			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Calculus urinary			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic kidney disease			
subjects affected / exposed	14 / 2402 (0.58%)	13 / 2419 (0.54%)	27 / 4821 (0.56%)
occurrences causally related to treatment / all	5 / 16	3 / 13	8 / 29
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysuria			

subjects affected / exposed	2 / 2402 (0.08%)	0 / 2419 (0.00%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
End stage renal disease			
subjects affected / exposed	3 / 2402 (0.12%)	3 / 2419 (0.12%)	6 / 4821 (0.12%)
occurrences causally related to treatment / all	0 / 4	0 / 3	0 / 7
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 2
Glomerulonephritis			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Glomerulonephropathy			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematuria			
subjects affected / exposed	8 / 2402 (0.33%)	5 / 2419 (0.21%)	13 / 4821 (0.27%)
occurrences causally related to treatment / all	0 / 9	0 / 5	0 / 14
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhage urinary tract			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hydronephrosis			
subjects affected / exposed	3 / 2402 (0.12%)	2 / 2419 (0.08%)	5 / 4821 (0.10%)
occurrences causally related to treatment / all	0 / 3	0 / 2	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephrolithiasis			
subjects affected / exposed	5 / 2402 (0.21%)	3 / 2419 (0.12%)	8 / 4821 (0.17%)
occurrences causally related to treatment / all	0 / 5	0 / 5	0 / 10
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephropathy toxic			

subjects affected / exposed	3 / 2402 (0.12%)	0 / 2419 (0.00%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Nephrotic syndrome			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oliguria			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prerenal failure			
subjects affected / exposed	3 / 2402 (0.12%)	1 / 2419 (0.04%)	4 / 4821 (0.08%)
occurrences causally related to treatment / all	1 / 3	0 / 1	1 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Proteinuria			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal artery stenosis			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal colic			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal cyst			
subjects affected / exposed	2 / 2402 (0.08%)	0 / 2419 (0.00%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal disorder			

subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			
subjects affected / exposed	29 / 2402 (1.21%)	31 / 2419 (1.28%)	60 / 4821 (1.24%)
occurrences causally related to treatment / all	5 / 33	10 / 36	15 / 69
deaths causally related to treatment / all	0 / 5	0 / 5	0 / 10
Renal impairment			
subjects affected / exposed	48 / 2402 (2.00%)	24 / 2419 (0.99%)	72 / 4821 (1.49%)
occurrences causally related to treatment / all	17 / 53	11 / 25	28 / 78
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 2
Renal infarct			
subjects affected / exposed	0 / 2402 (0.00%)	3 / 2419 (0.12%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 2	0 / 2
Renal injury			
subjects affected / exposed	2 / 2402 (0.08%)	0 / 2419 (0.00%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal mass			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal pain			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal tubular necrosis			
subjects affected / exposed	3 / 2402 (0.12%)	0 / 2419 (0.00%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal vein stenosis			

subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ureteric obstruction			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Ureterolithiasis			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urethral stenosis			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary incontinence			
subjects affected / exposed	3 / 2402 (0.12%)	1 / 2419 (0.04%)	4 / 4821 (0.08%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary retention			
subjects affected / exposed	8 / 2402 (0.33%)	8 / 2419 (0.33%)	16 / 4821 (0.33%)
occurrences causally related to treatment / all	0 / 8	0 / 9	0 / 17
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract obstruction			
subjects affected / exposed	0 / 2402 (0.00%)	2 / 2419 (0.08%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Goitre			
subjects affected / exposed	3 / 2402 (0.12%)	0 / 2419 (0.00%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypercorticoidism			

subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperparathyroidism			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperthyroidism			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypothyroidism			
subjects affected / exposed	3 / 2402 (0.12%)	3 / 2419 (0.12%)	6 / 4821 (0.12%)
occurrences causally related to treatment / all	0 / 3	0 / 3	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inappropriate antidiuretic hormone secretion			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Parathyroid hyperplasia			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Acquired claw toe			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthralgia			
subjects affected / exposed	7 / 2402 (0.29%)	4 / 2419 (0.17%)	11 / 4821 (0.23%)
occurrences causally related to treatment / all	0 / 8	0 / 4	0 / 12
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthritis			

subjects affected / exposed	3 / 2402 (0.12%)	5 / 2419 (0.21%)	8 / 4821 (0.17%)
occurrences causally related to treatment / all	0 / 3	0 / 5	0 / 8
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Back pain			
subjects affected / exposed	11 / 2402 (0.46%)	11 / 2419 (0.45%)	22 / 4821 (0.46%)
occurrences causally related to treatment / all	0 / 12	0 / 12	0 / 24
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bursitis			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CREST syndrome			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest wall haematoma			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chondrocalcinosis			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Costochondritis			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dactylitis			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dupuytren's contracture			

subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Exostosis			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fibromyalgia			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Flank pain			
subjects affected / exposed	0 / 2402 (0.00%)	3 / 2419 (0.12%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foot deformity			
subjects affected / exposed	1 / 2402 (0.04%)	3 / 2419 (0.12%)	4 / 4821 (0.08%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gouty arthritis			
subjects affected / exposed	1 / 2402 (0.04%)	3 / 2419 (0.12%)	4 / 4821 (0.08%)
occurrences causally related to treatment / all	0 / 1	0 / 4	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemarthrosis			
subjects affected / exposed	2 / 2402 (0.08%)	1 / 2419 (0.04%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral disc degeneration			
subjects affected / exposed	2 / 2402 (0.08%)	0 / 2419 (0.00%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral disc disorder			

subjects affected / exposed	3 / 2402 (0.12%)	0 / 2419 (0.00%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral disc protrusion			
subjects affected / exposed	5 / 2402 (0.21%)	9 / 2419 (0.37%)	14 / 4821 (0.29%)
occurrences causally related to treatment / all	0 / 5	0 / 11	0 / 16
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Joint effusion			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Kyphosis			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lumbar spinal stenosis			
subjects affected / exposed	5 / 2402 (0.21%)	4 / 2419 (0.17%)	9 / 4821 (0.19%)
occurrences causally related to treatment / all	0 / 6	0 / 4	0 / 10
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mobility decreased			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscle spasms			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscular weakness			
subjects affected / exposed	4 / 2402 (0.17%)	3 / 2419 (0.12%)	7 / 4821 (0.15%)
occurrences causally related to treatment / all	0 / 4	0 / 3	0 / 7
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal chest pain			

subjects affected / exposed	3 / 2402 (0.12%)	0 / 2419 (0.00%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal pain			
subjects affected / exposed	2 / 2402 (0.08%)	2 / 2419 (0.08%)	4 / 4821 (0.08%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myalgia			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myositis			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myositis ossificans			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neck pain			
subjects affected / exposed	1 / 2402 (0.04%)	2 / 2419 (0.08%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteitis			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteitis deformans			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoarthritis			

subjects affected / exposed	28 / 2402 (1.17%)	31 / 2419 (1.28%)	59 / 4821 (1.22%)
occurrences causally related to treatment / all	0 / 31	0 / 39	0 / 70
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteochondrosis			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteonecrosis			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoporosis			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain in extremity			
subjects affected / exposed	6 / 2402 (0.25%)	2 / 2419 (0.08%)	8 / 4821 (0.17%)
occurrences causally related to treatment / all	0 / 6	0 / 3	0 / 9
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pathological fracture			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Periarthritis			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Periostitis			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Polymyalgia rheumatica			

subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pseudarthrosis			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rheumatoid arthritis			
subjects affected / exposed	3 / 2402 (0.12%)	0 / 2419 (0.00%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rotator cuff syndrome			
subjects affected / exposed	3 / 2402 (0.12%)	6 / 2419 (0.25%)	9 / 4821 (0.19%)
occurrences causally related to treatment / all	0 / 3	0 / 6	0 / 9
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Scleroderma			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Spinal osteoarthritis			
subjects affected / exposed	4 / 2402 (0.17%)	6 / 2419 (0.25%)	10 / 4821 (0.21%)
occurrences causally related to treatment / all	0 / 4	0 / 6	0 / 10
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal pain			
subjects affected / exposed	6 / 2402 (0.25%)	3 / 2419 (0.12%)	9 / 4821 (0.19%)
occurrences causally related to treatment / all	0 / 7	0 / 3	0 / 10
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal stenosis			
subjects affected / exposed	6 / 2402 (0.25%)	5 / 2419 (0.21%)	11 / 4821 (0.23%)
occurrences causally related to treatment / all	0 / 6	0 / 7	0 / 13
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spondylolisthesis			

subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Synovial cyst			
subjects affected / exposed	0 / 2402 (0.00%)	2 / 2419 (0.08%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tenosynovitis			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Abdominal sepsis			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal wall abscess			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abscess jaw			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abscess limb			
subjects affected / exposed	0 / 2402 (0.00%)	2 / 2419 (0.08%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abscess neck			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Abscess oral			

subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acinetobacter bacteraemia			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute endocarditis			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Amoebiasis			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal abscess			
subjects affected / exposed	3 / 2402 (0.12%)	0 / 2419 (0.00%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 5	0 / 0	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis			
subjects affected / exposed	4 / 2402 (0.17%)	2 / 2419 (0.08%)	6 / 4821 (0.12%)
occurrences causally related to treatment / all	0 / 5	0 / 2	0 / 7
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Arthritis bacterial			
subjects affected / exposed	6 / 2402 (0.25%)	3 / 2419 (0.12%)	9 / 4821 (0.19%)
occurrences causally related to treatment / all	0 / 8	0 / 5	0 / 13
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthritis infective			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspergillus infection			

subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Bacteraemia			
subjects affected / exposed	7 / 2402 (0.29%)	6 / 2419 (0.25%)	13 / 4821 (0.27%)
occurrences causally related to treatment / all	0 / 9	0 / 7	0 / 16
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 2
Bacterial disease carrier			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacterial infection			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacterial rhinitis			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacterial sepsis			
subjects affected / exposed	2 / 2402 (0.08%)	0 / 2419 (0.00%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Beta haemolytic streptococcal infection			
subjects affected / exposed	2 / 2402 (0.08%)	0 / 2419 (0.00%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Biliary sepsis			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Biliary tract infection			

subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone abscess			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchiolitis			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis			
subjects affected / exposed	41 / 2402 (1.71%)	32 / 2419 (1.32%)	73 / 4821 (1.51%)
occurrences causally related to treatment / all	0 / 50	0 / 39	0 / 89
deaths causally related to treatment / all	0 / 0	0 / 2	0 / 2
Bronchitis viral			
subjects affected / exposed	2 / 2402 (0.08%)	0 / 2419 (0.00%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Campylobacter infection			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	25 / 2402 (1.04%)	30 / 2419 (1.24%)	55 / 4821 (1.14%)
occurrences causally related to treatment / all	0 / 35	0 / 38	0 / 73
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Chest wall abscess			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholangitis infective			

subjects affected / exposed	0 / 2402 (0.00%)	2 / 2419 (0.08%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Chronic sinusitis			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium colitis			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile colitis			
subjects affected / exposed	3 / 2402 (0.12%)	6 / 2419 (0.25%)	9 / 4821 (0.19%)
occurrences causally related to treatment / all	0 / 3	0 / 7	0 / 10
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Clostridium difficile infection			
subjects affected / exposed	2 / 2402 (0.08%)	3 / 2419 (0.12%)	5 / 4821 (0.10%)
occurrences causally related to treatment / all	0 / 2	0 / 3	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colonic abscess			
subjects affected / exposed	2 / 2402 (0.08%)	1 / 2419 (0.04%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Complicated appendicitis			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cystitis			
subjects affected / exposed	1 / 2402 (0.04%)	2 / 2419 (0.08%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cystitis bacterial			

subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cystitis escherichia			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cytomegalovirus infection			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dengue fever			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			
subjects affected / exposed	1 / 2402 (0.04%)	2 / 2419 (0.08%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetic foot infection			
subjects affected / exposed	2 / 2402 (0.08%)	1 / 2419 (0.04%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetic gangrene			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea infectious			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			

subjects affected / exposed	9 / 2402 (0.37%)	3 / 2419 (0.12%)	12 / 4821 (0.25%)
occurrences causally related to treatment / all	0 / 10	0 / 3	0 / 13
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Eczema infected			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Embolic pneumonia			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocarditis			
subjects affected / exposed	3 / 2402 (0.12%)	2 / 2419 (0.08%)	5 / 4821 (0.10%)
occurrences causally related to treatment / all	0 / 5	0 / 2	0 / 7
deaths causally related to treatment / all	0 / 1	0 / 2	0 / 3
Enteritis infectious			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterococcal bacteraemia			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterococcal sepsis			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epididymitis			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epiglottitis			

subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erysipelas			
subjects affected / exposed	7 / 2402 (0.29%)	11 / 2419 (0.45%)	18 / 4821 (0.37%)
occurrences causally related to treatment / all	0 / 8	0 / 15	0 / 23
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia bacteraemia			
subjects affected / exposed	2 / 2402 (0.08%)	0 / 2419 (0.00%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia sepsis			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia urinary tract infection			
subjects affected / exposed	1 / 2402 (0.04%)	2 / 2419 (0.08%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gangrene			
subjects affected / exposed	3 / 2402 (0.12%)	3 / 2419 (0.12%)	6 / 4821 (0.12%)
occurrences causally related to treatment / all	0 / 3	0 / 3	0 / 6
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Gastroenteritis			
subjects affected / exposed	16 / 2402 (0.67%)	21 / 2419 (0.87%)	37 / 4821 (0.77%)
occurrences causally related to treatment / all	0 / 16	0 / 21	0 / 37
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Gastroenteritis bacterial			
subjects affected / exposed	2 / 2402 (0.08%)	0 / 2419 (0.00%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis clostridial			

subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis norovirus			
subjects affected / exposed	2 / 2402 (0.08%)	0 / 2419 (0.00%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis salmonella			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis viral			
subjects affected / exposed	1 / 2402 (0.04%)	2 / 2419 (0.08%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal viral infection			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Genital herpes zoster			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematoma infection			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Helicobacter infection			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatitis E			

subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
subjects affected / exposed	4 / 2402 (0.17%)	2 / 2419 (0.08%)	6 / 4821 (0.12%)
occurrences causally related to treatment / all	0 / 4	0 / 2	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hordeolum			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Human anaplasmosis			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infected skin ulcer			
subjects affected / exposed	4 / 2402 (0.17%)	2 / 2419 (0.08%)	6 / 4821 (0.12%)
occurrences causally related to treatment / all	0 / 4	0 / 2	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection			
subjects affected / exposed	3 / 2402 (0.12%)	1 / 2419 (0.04%)	4 / 4821 (0.08%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infectious pleural effusion			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infective exacerbation of bronchiectasis			
subjects affected / exposed	2 / 2402 (0.08%)	1 / 2419 (0.04%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infective exacerbation of chronic obstructive airways disease			

subjects affected / exposed	3 / 2402 (0.12%)	2 / 2419 (0.08%)	5 / 4821 (0.10%)
occurrences causally related to treatment / all	0 / 3	0 / 2	0 / 5
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Influenza			
subjects affected / exposed	11 / 2402 (0.46%)	16 / 2419 (0.66%)	27 / 4821 (0.56%)
occurrences causally related to treatment / all	0 / 11	0 / 16	0 / 27
deaths causally related to treatment / all	0 / 2	0 / 1	0 / 3
Intervertebral discitis			
subjects affected / exposed	2 / 2402 (0.08%)	1 / 2419 (0.04%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal sepsis			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intracranial infection			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Klebsiella sepsis			
subjects affected / exposed	0 / 2402 (0.00%)	2 / 2419 (0.08%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Labyrinthitis			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngitis			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Liver abscess			

subjects affected / exposed	2 / 2402 (0.08%)	0 / 2419 (0.00%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Localised infection			
subjects affected / exposed	5 / 2402 (0.21%)	4 / 2419 (0.17%)	9 / 4821 (0.19%)
occurrences causally related to treatment / all	0 / 6	0 / 4	0 / 10
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Lower respiratory tract infection			
subjects affected / exposed	12 / 2402 (0.50%)	11 / 2419 (0.45%)	23 / 4821 (0.48%)
occurrences causally related to treatment / all	0 / 14	0 / 11	0 / 25
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Lower respiratory tract infection viral			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung abscess			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung infection			
subjects affected / exposed	11 / 2402 (0.46%)	12 / 2419 (0.50%)	23 / 4821 (0.48%)
occurrences causally related to treatment / all	0 / 12	0 / 13	0 / 25
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Lymphangitis			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mediastinitis			
subjects affected / exposed	2 / 2402 (0.08%)	0 / 2419 (0.00%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Medical device site infection			

subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningitis enterococcal			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nasopharyngitis			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Necrotising fasciitis			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nosocomial infection			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal candidiasis			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ophthalmic herpes zoster			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oral candidiasis			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oral herpes			

subjects affected / exposed	0 / 2402 (0.00%)	2 / 2419 (0.08%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Orchitis			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteomyelitis			
subjects affected / exposed	3 / 2402 (0.12%)	7 / 2419 (0.29%)	10 / 4821 (0.21%)
occurrences causally related to treatment / all	0 / 3	0 / 9	0 / 12
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Otitis media			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pelvic abscess			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Periodontitis			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonitis			
subjects affected / exposed	2 / 2402 (0.08%)	0 / 2419 (0.00%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonitis bacterial			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pharyngitis			

subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumococcal sepsis			
subjects affected / exposed	0 / 2402 (0.00%)	3 / 2419 (0.12%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Pneumonia			
subjects affected / exposed	178 / 2402 (7.41%)	162 / 2419 (6.70%)	340 / 4821 (7.05%)
occurrences causally related to treatment / all	0 / 212	0 / 197	0 / 409
deaths causally related to treatment / all	0 / 24	0 / 23	0 / 47
Pneumonia bacterial			
subjects affected / exposed	5 / 2402 (0.21%)	4 / 2419 (0.17%)	9 / 4821 (0.19%)
occurrences causally related to treatment / all	0 / 5	0 / 4	0 / 9
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia influenzal			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Pneumonia mycoplasmal			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia pneumococcal			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia respiratory syncytial viral			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia streptococcal			

subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia viral			
subjects affected / exposed	1 / 2402 (0.04%)	2 / 2419 (0.08%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural infection			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative wound infection			
subjects affected / exposed	3 / 2402 (0.12%)	3 / 2419 (0.12%)	6 / 4821 (0.12%)
occurrences causally related to treatment / all	0 / 3	1 / 3	1 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pseudomembranous colitis			
subjects affected / exposed	2 / 2402 (0.08%)	1 / 2419 (0.04%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary sepsis			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary tuberculosis			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Pyelonephritis			
subjects affected / exposed	3 / 2402 (0.12%)	3 / 2419 (0.12%)	6 / 4821 (0.12%)
occurrences causally related to treatment / all	0 / 3	0 / 3	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis acute			

subjects affected / exposed	3 / 2402 (0.12%)	4 / 2419 (0.17%)	7 / 4821 (0.15%)
occurrences causally related to treatment / all	0 / 3	0 / 4	0 / 7
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis chronic			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal abscess			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal abscess			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory moniliasis			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus bronchitis			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus infection			
subjects affected / exposed	2 / 2402 (0.08%)	1 / 2419 (0.04%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			
subjects affected / exposed	21 / 2402 (0.87%)	19 / 2419 (0.79%)	40 / 4821 (0.83%)
occurrences causally related to treatment / all	0 / 25	0 / 21	0 / 46
deaths causally related to treatment / all	0 / 0	0 / 3	0 / 3
Respiratory tract infection bacterial			

subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection viral			
subjects affected / exposed	2 / 2402 (0.08%)	1 / 2419 (0.04%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Salmonellosis			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	37 / 2402 (1.54%)	34 / 2419 (1.41%)	71 / 4821 (1.47%)
occurrences causally related to treatment / all	1 / 44	0 / 41	1 / 85
deaths causally related to treatment / all	0 / 9	0 / 12	0 / 21
Septic encephalopathy			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic necrosis			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	16 / 2402 (0.67%)	21 / 2419 (0.87%)	37 / 4821 (0.77%)
occurrences causally related to treatment / all	0 / 17	0 / 23	0 / 40
deaths causally related to treatment / all	0 / 10	0 / 10	0 / 20
Severe acute respiratory syndrome			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Shunt infection			

subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin bacterial infection			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin infection			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Soft tissue infection			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal bacteraemia			
subjects affected / exposed	3 / 2402 (0.12%)	0 / 2419 (0.00%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 4	0 / 0	0 / 4
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Staphylococcal infection			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal sepsis			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Streptococcal bacteraemia			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Streptococcal sepsis			

subjects affected / exposed	3 / 2402 (0.12%)	0 / 2419 (0.00%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syphilis			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tooth abscess			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tracheobronchitis			
subjects affected / exposed	2 / 2402 (0.08%)	2 / 2419 (0.08%)	4 / 4821 (0.08%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tuberculosis			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Tuberculous pleurisy			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tubo-ovarian abscess			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	6 / 2402 (0.25%)	5 / 2419 (0.21%)	11 / 4821 (0.23%)
occurrences causally related to treatment / all	0 / 6	0 / 5	0 / 11
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urethritis			

subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	68 / 2402 (2.83%)	54 / 2419 (2.23%)	122 / 4821 (2.53%)
occurrences causally related to treatment / all	0 / 76	0 / 68	0 / 144
deaths causally related to treatment / all	0 / 0	0 / 2	0 / 2
Urosepsis			
subjects affected / exposed	14 / 2402 (0.58%)	11 / 2419 (0.45%)	25 / 4821 (0.52%)
occurrences causally related to treatment / all	0 / 14	0 / 12	0 / 26
deaths causally related to treatment / all	0 / 2	0 / 2	0 / 4
Vestibular neuronitis			
subjects affected / exposed	1 / 2402 (0.04%)	2 / 2419 (0.08%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral infection			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral upper respiratory tract infection			
subjects affected / exposed	1 / 2402 (0.04%)	2 / 2419 (0.08%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound abscess			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound infection			
subjects affected / exposed	3 / 2402 (0.12%)	2 / 2419 (0.08%)	5 / 4821 (0.10%)
occurrences causally related to treatment / all	0 / 3	0 / 2	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Cachexia			

subjects affected / exposed	1 / 2402 (0.04%)	2 / 2419 (0.08%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 1	0 / 2	0 / 3
Cardiometabolic syndrome			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Decreased appetite			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Dehydration			
subjects affected / exposed	26 / 2402 (1.08%)	18 / 2419 (0.74%)	44 / 4821 (0.91%)
occurrences causally related to treatment / all	1 / 30	1 / 18	2 / 48
deaths causally related to treatment / all	0 / 3	0 / 0	0 / 3
Diabetes mellitus			
subjects affected / exposed	8 / 2402 (0.33%)	9 / 2419 (0.37%)	17 / 4821 (0.35%)
occurrences causally related to treatment / all	0 / 9	0 / 9	0 / 18
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Diabetes mellitus inadequate control			
subjects affected / exposed	3 / 2402 (0.12%)	4 / 2419 (0.17%)	7 / 4821 (0.15%)
occurrences causally related to treatment / all	0 / 3	0 / 4	0 / 7
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetic complication			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Diabetic ketoacidosis			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetic metabolic decompensation			

subjects affected / exposed	9 / 2402 (0.37%)	3 / 2419 (0.12%)	12 / 4821 (0.25%)
occurrences causally related to treatment / all	1 / 11	0 / 3	1 / 14
deaths causally related to treatment / all	1 / 1	0 / 0	1 / 1
Electrolyte imbalance			
subjects affected / exposed	2 / 2402 (0.08%)	0 / 2419 (0.00%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Failure to thrive			
subjects affected / exposed	1 / 2402 (0.04%)	2 / 2419 (0.08%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fluid overload			
subjects affected / exposed	8 / 2402 (0.33%)	8 / 2419 (0.33%)	16 / 4821 (0.33%)
occurrences causally related to treatment / all	1 / 8	1 / 11	2 / 19
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Fluid retention			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Folate deficiency			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gout			
subjects affected / exposed	11 / 2402 (0.46%)	5 / 2419 (0.21%)	16 / 4821 (0.33%)
occurrences causally related to treatment / all	1 / 11	0 / 5	1 / 16
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Haemochromatosis			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperammonaemia			

subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypercalcaemia			
subjects affected / exposed	2 / 2402 (0.08%)	2 / 2419 (0.08%)	4 / 4821 (0.08%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Hypercholesterolaemia			
subjects affected / exposed	1 / 2402 (0.04%)	0 / 2419 (0.00%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	16 / 2402 (0.67%)	10 / 2419 (0.41%)	26 / 4821 (0.54%)
occurrences causally related to treatment / all	0 / 18	0 / 15	0 / 33
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 2
Hyperglycaemic hyperosmolar nonketotic syndrome			
subjects affected / exposed	1 / 2402 (0.04%)	2 / 2419 (0.08%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperkalaemia			
subjects affected / exposed	42 / 2402 (1.75%)	19 / 2419 (0.79%)	61 / 4821 (1.27%)
occurrences causally related to treatment / all	28 / 51	6 / 21	34 / 72
deaths causally related to treatment / all	0 / 1	0 / 2	0 / 3
Hypernatraemia			
subjects affected / exposed	0 / 2402 (0.00%)	3 / 2419 (0.12%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 0	0 / 4	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperuricaemia			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoalbuminaemia			

subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypocalcaemia			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoglycaemia			
subjects affected / exposed	6 / 2402 (0.25%)	20 / 2419 (0.83%)	26 / 4821 (0.54%)
occurrences causally related to treatment / all	0 / 6	0 / 20	0 / 26
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Hypokalaemia			
subjects affected / exposed	14 / 2402 (0.58%)	8 / 2419 (0.33%)	22 / 4821 (0.46%)
occurrences causally related to treatment / all	1 / 15	0 / 9	1 / 24
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Hypomagnesaemia			
subjects affected / exposed	1 / 2402 (0.04%)	2 / 2419 (0.08%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	17 / 2402 (0.71%)	17 / 2419 (0.70%)	34 / 4821 (0.71%)
occurrences causally related to treatment / all	1 / 21	1 / 19	2 / 40
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoosmolar state			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypophosphataemia			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypovolaemia			

subjects affected / exposed	1 / 2402 (0.04%)	4 / 2419 (0.17%)	5 / 4821 (0.10%)
occurrences causally related to treatment / all	1 / 1	1 / 5	2 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Iron deficiency			
subjects affected / exposed	4 / 2402 (0.17%)	0 / 2419 (0.00%)	4 / 4821 (0.08%)
occurrences causally related to treatment / all	0 / 4	0 / 0	0 / 4
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Ketoacidosis			
subjects affected / exposed	0 / 2402 (0.00%)	1 / 2419 (0.04%)	1 / 4821 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lactic acidosis			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malnutrition			
subjects affected / exposed	3 / 2402 (0.12%)	0 / 2419 (0.00%)	3 / 4821 (0.06%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Marasmus			
subjects affected / exposed	1 / 2402 (0.04%)	1 / 2419 (0.04%)	2 / 4821 (0.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 2
Metabolic acidosis			
subjects affected / exposed	3 / 2402 (0.12%)	3 / 2419 (0.12%)	6 / 4821 (0.12%)
occurrences causally related to treatment / all	0 / 3	0 / 3	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Type 2 diabetes mellitus			
subjects affected / exposed	8 / 2402 (0.33%)	5 / 2419 (0.21%)	13 / 4821 (0.27%)
occurrences causally related to treatment / all	0 / 8	0 / 5	0 / 13
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 2 %

Non-serious adverse events	Valsartan	LCZ696	All patients
Total subjects affected by non-serious adverse events			
subjects affected / exposed	1995 / 2402 (83.06%)	2005 / 2419 (82.89%)	4000 / 4821 (82.97%)
Vascular disorders			
Hypertension			
subjects affected / exposed	314 / 2402 (13.07%)	225 / 2419 (9.30%)	539 / 4821 (11.18%)
occurrences (all)	403	264	667
Hypotension			
subjects affected / exposed	379 / 2402 (15.78%)	529 / 2419 (21.87%)	908 / 4821 (18.83%)
occurrences (all)	505	749	1254
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	58 / 2402 (2.41%)	60 / 2419 (2.48%)	118 / 4821 (2.45%)
occurrences (all)	62	71	133
Fatigue			
subjects affected / exposed	107 / 2402 (4.45%)	98 / 2419 (4.05%)	205 / 4821 (4.25%)
occurrences (all)	118	115	233
Non-cardiac chest pain			
subjects affected / exposed	92 / 2402 (3.83%)	98 / 2419 (4.05%)	190 / 4821 (3.94%)
occurrences (all)	103	115	218
Oedema peripheral			
subjects affected / exposed	183 / 2402 (7.62%)	166 / 2419 (6.86%)	349 / 4821 (7.24%)
occurrences (all)	221	202	423
Pyrexia			
subjects affected / exposed	54 / 2402 (2.25%)	59 / 2419 (2.44%)	113 / 4821 (2.34%)
occurrences (all)	65	76	141
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			
subjects affected / exposed	68 / 2402 (2.83%)	57 / 2419 (2.36%)	125 / 4821 (2.59%)
occurrences (all)	86	69	155
Cough			

subjects affected / exposed	146 / 2402 (6.08%)	188 / 2419 (7.77%)	334 / 4821 (6.93%)
occurrences (all)	174	234	408
Dyspnoea			
subjects affected / exposed	236 / 2402 (9.83%)	217 / 2419 (8.97%)	453 / 4821 (9.40%)
occurrences (all)	291	262	553
Epistaxis			
subjects affected / exposed	71 / 2402 (2.96%)	42 / 2419 (1.74%)	113 / 4821 (2.34%)
occurrences (all)	85	46	131
Psychiatric disorders			
Depression			
subjects affected / exposed	70 / 2402 (2.91%)	68 / 2419 (2.81%)	138 / 4821 (2.86%)
occurrences (all)	71	69	140
Insomnia			
subjects affected / exposed	54 / 2402 (2.25%)	75 / 2419 (3.10%)	129 / 4821 (2.68%)
occurrences (all)	56	85	141
Investigations			
Blood creatinine increased			
subjects affected / exposed	65 / 2402 (2.71%)	63 / 2419 (2.60%)	128 / 4821 (2.66%)
occurrences (all)	77	70	147
Glomerular filtration rate decreased			
subjects affected / exposed	93 / 2402 (3.87%)	85 / 2419 (3.51%)	178 / 4821 (3.69%)
occurrences (all)	116	101	217
Weight decreased			
subjects affected / exposed	82 / 2402 (3.41%)	71 / 2419 (2.94%)	153 / 4821 (3.17%)
occurrences (all)	90	74	164
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	72 / 2402 (3.00%)	57 / 2419 (2.36%)	129 / 4821 (2.68%)
occurrences (all)	83	62	145
Fall			
subjects affected / exposed	90 / 2402 (3.75%)	106 / 2419 (4.38%)	196 / 4821 (4.07%)
occurrences (all)	127	128	255
Cardiac disorders			
Angina pectoris			
subjects affected / exposed	82 / 2402 (3.41%)	87 / 2419 (3.60%)	169 / 4821 (3.51%)
occurrences (all)	104	105	209

Atrial fibrillation			
subjects affected / exposed	239 / 2402 (9.95%)	248 / 2419 (10.25%)	487 / 4821 (10.10%)
occurrences (all)	297	318	615
Bradycardia			
subjects affected / exposed	85 / 2402 (3.54%)	53 / 2419 (2.19%)	138 / 4821 (2.86%)
occurrences (all)	90	57	147
Cardiac failure			
subjects affected / exposed	269 / 2402 (11.20%)	225 / 2419 (9.30%)	494 / 4821 (10.25%)
occurrences (all)	376	304	680
Palpitations			
subjects affected / exposed	56 / 2402 (2.33%)	62 / 2419 (2.56%)	118 / 4821 (2.45%)
occurrences (all)	66	70	136
Nervous system disorders			
Dizziness			
subjects affected / exposed	192 / 2402 (7.99%)	229 / 2419 (9.47%)	421 / 4821 (8.73%)
occurrences (all)	213	298	511
Headache			
subjects affected / exposed	126 / 2402 (5.25%)	114 / 2419 (4.71%)	240 / 4821 (4.98%)
occurrences (all)	139	131	270
Syncope			
subjects affected / exposed	62 / 2402 (2.58%)	42 / 2419 (1.74%)	104 / 4821 (2.16%)
occurrences (all)	73	50	123
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	214 / 2402 (8.91%)	166 / 2419 (6.86%)	380 / 4821 (7.88%)
occurrences (all)	242	182	424
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	60 / 2402 (2.50%)	77 / 2419 (3.18%)	137 / 4821 (2.84%)
occurrences (all)	64	83	147
Eye disorders			
Cataract			
subjects affected / exposed	70 / 2402 (2.91%)	84 / 2419 (3.47%)	154 / 4821 (3.19%)
occurrences (all)	83	105	188
Gastrointestinal disorders			

Abdominal pain			
subjects affected / exposed	54 / 2402 (2.25%)	53 / 2419 (2.19%)	107 / 4821 (2.22%)
occurrences (all)	58	57	115
Constipation			
subjects affected / exposed	86 / 2402 (3.58%)	100 / 2419 (4.13%)	186 / 4821 (3.86%)
occurrences (all)	93	108	201
Diarrhoea			
subjects affected / exposed	180 / 2402 (7.49%)	177 / 2419 (7.32%)	357 / 4821 (7.41%)
occurrences (all)	212	214	426
Nausea			
subjects affected / exposed	87 / 2402 (3.62%)	93 / 2419 (3.84%)	180 / 4821 (3.73%)
occurrences (all)	106	100	206
Vomiting			
subjects affected / exposed	58 / 2402 (2.41%)	70 / 2419 (2.89%)	128 / 4821 (2.66%)
occurrences (all)	65	78	143
Skin and subcutaneous tissue disorders			
Pruritus			
subjects affected / exposed	51 / 2402 (2.12%)	46 / 2419 (1.90%)	97 / 4821 (2.01%)
occurrences (all)	55	56	111
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	65 / 2402 (2.71%)	64 / 2419 (2.65%)	129 / 4821 (2.68%)
occurrences (all)	85	83	168
Chronic kidney disease			
subjects affected / exposed	50 / 2402 (2.08%)	33 / 2419 (1.36%)	83 / 4821 (1.72%)
occurrences (all)	56	36	92
Haematuria			
subjects affected / exposed	77 / 2402 (3.21%)	71 / 2419 (2.94%)	148 / 4821 (3.07%)
occurrences (all)	84	79	163
Renal failure			
subjects affected / exposed	108 / 2402 (4.50%)	85 / 2419 (3.51%)	193 / 4821 (4.00%)
occurrences (all)	138	94	232
Renal impairment			
subjects affected / exposed	331 / 2402 (13.78%)	287 / 2419 (11.86%)	618 / 4821 (12.82%)
occurrences (all)	414	347	761
Musculoskeletal and connective tissue disorders			

Arthralgia			
subjects affected / exposed	153 / 2402 (6.37%)	152 / 2419 (6.28%)	305 / 4821 (6.33%)
occurrences (all)	186	178	364
Back pain			
subjects affected / exposed	170 / 2402 (7.08%)	149 / 2419 (6.16%)	319 / 4821 (6.62%)
occurrences (all)	191	166	357
Muscle spasms			
subjects affected / exposed	49 / 2402 (2.04%)	36 / 2419 (1.49%)	85 / 4821 (1.76%)
occurrences (all)	56	39	95
Musculoskeletal pain			
subjects affected / exposed	58 / 2402 (2.41%)	63 / 2419 (2.60%)	121 / 4821 (2.51%)
occurrences (all)	63	69	132
Osteoarthritis			
subjects affected / exposed	92 / 2402 (3.83%)	92 / 2419 (3.80%)	184 / 4821 (3.82%)
occurrences (all)	105	112	217
Pain in extremity			
subjects affected / exposed	75 / 2402 (3.12%)	81 / 2419 (3.35%)	156 / 4821 (3.24%)
occurrences (all)	84	87	171
Infections and infestations			
Bronchitis			
subjects affected / exposed	197 / 2402 (8.20%)	177 / 2419 (7.32%)	374 / 4821 (7.76%)
occurrences (all)	234	217	451
Cellulitis			
subjects affected / exposed	41 / 2402 (1.71%)	61 / 2419 (2.52%)	102 / 4821 (2.12%)
occurrences (all)	50	68	118
Influenza			
subjects affected / exposed	109 / 2402 (4.54%)	110 / 2419 (4.55%)	219 / 4821 (4.54%)
occurrences (all)	120	130	250
Nasopharyngitis			
subjects affected / exposed	177 / 2402 (7.37%)	207 / 2419 (8.56%)	384 / 4821 (7.97%)
occurrences (all)	243	272	515
Pneumonia			
subjects affected / exposed	97 / 2402 (4.04%)	100 / 2419 (4.13%)	197 / 4821 (4.09%)
occurrences (all)	114	105	219
Respiratory tract infection			

subjects affected / exposed	60 / 2402 (2.50%)	48 / 2419 (1.98%)	108 / 4821 (2.24%)
occurrences (all)	74	54	128
Upper respiratory tract infection			
subjects affected / exposed	139 / 2402 (5.79%)	145 / 2419 (5.99%)	284 / 4821 (5.89%)
occurrences (all)	185	197	382
Urinary tract infection			
subjects affected / exposed	268 / 2402 (11.16%)	243 / 2419 (10.05%)	511 / 4821 (10.60%)
occurrences (all)	382	328	710
Metabolism and nutrition disorders			
Diabetes mellitus			
subjects affected / exposed	62 / 2402 (2.58%)	52 / 2419 (2.15%)	114 / 4821 (2.36%)
occurrences (all)	65	57	122
Gout			
subjects affected / exposed	88 / 2402 (3.66%)	76 / 2419 (3.14%)	164 / 4821 (3.40%)
occurrences (all)	106	100	206
Hyperkalaemia			
subjects affected / exposed	298 / 2402 (12.41%)	238 / 2419 (9.84%)	536 / 4821 (11.12%)
occurrences (all)	423	325	748
Hyperuricaemia			
subjects affected / exposed	75 / 2402 (3.12%)	62 / 2419 (2.56%)	137 / 4821 (2.84%)
occurrences (all)	83	65	148
Hypokalaemia			
subjects affected / exposed	100 / 2402 (4.16%)	110 / 2419 (4.55%)	210 / 4821 (4.36%)
occurrences (all)	128	134	262

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
14 June 2014	The main purpose of this amendment was to increase the contraception period for women of child-bearing potential after being taken off study medication from 4 days to 7 days in exclusion criterion 33 in order to be consistent with the other study protocols from the LCZ696 clinical program and with the LCZ696 Investigators' Brochure. Updated TOPCAT study results and DMC's decision to stop PARADIGM study ahead of schedule in March 2014 based on the positive efficacy findings are included in the background of the study in Introduction.
06 May 2015	Modified several study objectives and endpoints (secondary and exploratory endpoints) and their associated analysis plans, included cognitive function assessments using the Mini-Mental State Examination (MMSE) instrument at baseline and annually thereafter, modified several entry criteria, moved the interim efficacy analysis to occur when approximately two-thirds of the primary composite events, rather than half as previously defined and eliminated the futility analysis.
04 December 2015	Administered KCCQ at the start of the run-in (i.e., Visit 101 or 102), whichever occurs first. Included a process for conducting a medical review of medical history of enrolled patients by a Novartis central review group to assess adherence to the inclusion/exclusion criteria. Adjust sample size from 4300 to 4600 to increase the statistical power from 81% to 85% to detect a 25% reduction in recurrent heart failure hospitalizations.
09 December 2015	The purpose of this amendment was to include changes required by the Japanese Health Authority (PMDA) and the Indian Health Authority. Changes made were only applicable to Japan and India.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported